20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847355] Number: PF-[ADDRESS_847356] Name: 20-valent pneumococcal conjugate vaccine 
(20vPnC)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:
Protocol Number: B7471011
Phase: 3
Short Title: 20-valent Pneumococcal Conjugate Vaccine Safet y and Immunogenicity Stud y 
in Healthy  Infants
 
 
 
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Amendment 2 01 April 2022 Section 1.3: Addition of text clarifying changes to Visits 5, 6 ,
and 7, including relevant calendar dates.
Section 2.1: Addition of text describing the ration ale for changes 
to the protocol.
Section 4.1: Addition of text describing changes to the overall 
design.
Section 6.3.2 : Changed the timing for unblinding of sponsor 
personnel from 1 month after Dose 3 to 1 month after Dose 4.
Section 7.2: Addition of text describing follow -up for 
participants discontinued prior to completing all 4 doses of study 
intervention .
Secti on 8.10.5 : Addition of text specifying the end date for 
Visit 5. Addition of guidance for discontinuation of participants 
after that date.
Section 8.10.6 : Addition of text specifying thelatest date for 
Visit [ADDRESS_847357] this 
visit b y phone after the cutoff date.
Section 8.10.7 : Addition of text specifying the latest date for 
Visit 7, and modifying study visit win dows based on the 
calendar date of the last vaccine dose.
Section 9.5.1 : Detail edchanges to the analysis timing ,as the 
analys es of Dose s3 and 4 are now  being done together.
Amendment 1 23 April 2020 Section 1 : Update of w ording to the Objectives, Estimands, and 
Endpoints and Statistical Methods.  The primary objective to 
compare IgG GMCs at the time point [ADDRESS_847358]
dose has been changed to a key secondary endpoint.  Added 
additional w ording to the objectives for clarification.
Section 3: Update of w ording to the Objectives, Estimands, and 
Endpoints.  The primary objectives to compare IgG GMCs at the 
time point [ADDRESS_847359] been changed to key 
secondary endpoints.  Added additional w ording to the 
objectives for clarification.
Section 9 : Update of w ording throughout the section  
(inparticular Sections [IP_ADDRESS] , 9.1.3 , 9.2.1, and 9.4.1 ) to reflect
that the primary objective to compare IgG GMCs at the time 
point [ADDRESS_847360] dose has been changed to a key 
secondary endpoint .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 3Document History
Document Version Date Summary of Changes and Rationale
Section 6.1.2 , Section 8.3.6 , Section 10.1.5 , and Section 10.8: 
Mandatory protocol template text updates.
Original protocol 19 February 2020 Not applicable (N/A)
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847361] OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY ...................................................................................................10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................16
1.3. Schedule of Activities (SoA) ...................................................................................17
2. INTRODUCTION ...............................................................................................................20
2.1. Study  Rationale .......................................................................................................24
2.2. Background .............................................................................................................24
2.2.1. Clinical Overview .......................................................................................25
2.3. Benefit/Risk Assessment
.........................................................................................25
3. OBJECTI VES, ESTIMANDS
, AND ENDPOINTS ...........................................................27
4. STUDY DESIGN .................................................................................................................32
4.1. Overall Design .........................................................................................................32
4.1.1. Approxi mate Duration of Participation for Each Participant .....................34
4.1.2. Approximate Number of Participants .........................................................34
4.2. Scientific Rationale for Study  Design .....................................................................34
4.3. Justification for Dose ..............................................................................................34
4.4. E nd of Study  Definition ..........................................................................................35
5. STUDY POPUL ATION
......................................................................................................35
5.1. I nclusion Criteria .....................................................................................................35
5.2. Exclusion Criteria ....................................................................................................36
5.3. L ifestyle Considerations ..........................................................................................37
5.4. Screen Failures ........................................................................................................37
5.5. Temporary  Delay  Criteria .......................................................................................38
5.5.1. Criteria for Temporaril y Dela ying Vaccine Administration ......................38
5.5.2. Criteria for Temporaril y Dela ying Immunogenicity  Blood Draw .............. 38
6. STUDY INTERVENTIO N................................ ................................ ................................ ..38
6.1. Study  Intervention(s) Administered ........................................................................38
6.1.1. Administration ............................................................................................39
6.1.2. Medical Devices .........................................................................................40

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 56.2. Preparation/Handling/Storage/Accountability ........................................................40
6.2.1. Preparation and Dispensing ........................................................................42
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................[ADDRESS_847362] .........................................................42
6.3.2. Blinding of the Sponsor
..............................................................................42
6.3.3. Breaking the Blind ......................................................................................42
6.4. Study  Intervention Compliance ...............................................................................43
6.5. Concomitant Therapy ..............................................................................................43
6.5.1. Prohibite d Concomitant Vaccines and Treatments .....................................43
6.5.2. Permitted Concomitant Vaccines and Treatments ......................................43
6.5.3. Recording Prior and Concomitant Vaccines and Treatments
.....................44
6.6. Dose Modification ...................................................................................................44
6.7. I ntervention After the End of the Study ..................................................................44
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................44
7.1. Discontinuation of Study  Intervention ....................................................................44
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_847363] to Follow -
up ....................................................................................................46
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................46
8.1. Efficacy  Assessments ..............................................................................................47
8.1.1. I mmunogenicit y Assessments ....................................................................47
8.1.2. Biological Samples .....................................................................................49
8.2. Safet y Assessments .................................................................................................49
8.2.1. Participant Electronic Diary ................................ ................................ .......50
8.2.2. Grading Scale for Prompted Events ...........................................................51
[IP_ADDRESS]. L ocal Reactions .........................................................................51
[IP_ADDRESS]. Sy stemic Events (Sy stemic S ymptoms and Fever) ...................52
[IP_ADDRESS]. Use of Antip yretic/Pain Medication ..........................................54
8.2.3. Clinical Safety  Laboratory  Assessments ....................................................54
8.3. Adverse Events and Serious Adverse Events
..........................................................54
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......54
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................55

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................55
8.3.2. Method of Detecting AEs and SAEs ..........................................................55
8.3.3. Follow -up of AEs and SAEs .......................................................................55
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................56
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................56
[IP_ADDRESS]. Exposure During Pregnancy ......................................................56
[IP_ADDRESS]. Exposure During Breastfeeding ................................................57
[IP_ADDRESS]. Occupational Exposure .............................................................57
8.3.6. Medical Device Deficiencies ......................................................................57
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies .........57
[IP_ADDRESS]. Follow -
up of Medical Device Deficiencies...............................58
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor ..............58
[IP_ADDRESS]. Regulatory  Reporting Requirements for Medical Device 
Deficiencies .......................................................................................58
8.3.7. Medication Errors .......................................................................................58
8.4. Treatment of Overdose
............................................................................................59
8.5. P harmacokinetics ....................................................................................................60
8.6.Pharmacod ynamics ..................................................................................................60
8.7. Genetics ...................................................................................................................60
8.8. Biomarkers ..............................................................................................................60
8.9. Health Economics ...................................................................................................60
8.10. Study  Procedures ...................................................................................................60
8.10.1. Visit 1 (Dose 1 Visit, Day  1) ....................................................................60
8.10.2. Visit 2 (Dose 2 Visit, 42 to 63 Day s After Dose 1, ie, Study  Day  43 
Through Stud y Da y 64) ...................................................................................62
8.10.3. Visit 3 (Dose 3 Visit, 42 to 63 Day s After Dose 2) ..................................63
8.10.4. Visit 4 (Dose 3 Follow -up Visit, 28 to 42 Day s After Dose 3) ................65
8.10.5. Visit 5 (Dose 4 Visit, 365 to 455 Day s of Age) ........................................65
8.10.6. Visit 6 (Dose 4 Follow -up Visit, 28 to 42 Day s After Dose 4) ................ 67
8.10.7. Visit 7 (Dose 4 6 -Month Visit, 168 to 196 Day s After Dose 4) ...............68
8.10.8. Unscheduled Visits ................................ ................................ ................... 68

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 79. STATI STICAL CONSI DERATIONS ................................................................................70
9.1. Estimands and Statistical Hy potheses .....................................................................70
9.1.1. Estimands ....................................................................................................70
9.1.2. Statistical Hy
potheses .................................................................................70
[IP_ADDRESS]. Pneumococcal Immunogenicit y Hypotheses .............................70
[IP_ADDRESS]. Concomitant I mmunogenicit y Hypotheses ...............................72
9.1.3. Multiplicity  Considerations
........................................................................73
9.2. Sample Size Determination .....................................................................................74
9.2.1. Sample Size Consideration for Primary  Pneumococcal 
Immunogenicit y Objectives .............................................................................74
9.2.2. Sample Size Consideration for Concomitant I mmunogenicit y 
Objectives ........................................................................................................76
9.3.Populations for Analysis .........................................................................................78
9.4. Statistical Analy ses.................................................................................................78
9.4.1. I mmunogenicit y Analyses ..........................................................................78
9.4.2. Safet y Anal yses..........................................................................................84
9.4.3.
Other Anal yses............................................................................................85
9.5. I nterim Anal yses.....................................................................................................85
9.5.1. Analy sis Timing ..........................................................................................86
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................87
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............87
10.1.1. Regulatory and Ethical Considerations ....................................................87
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................87
10.1.2. Financial Disclosure ................................ ................................ ................. 88
10.1.3. I nformed Consent Process ................................ ................................ ........ 88
10.1.4. Data Protection .........................................................................................89
10.1.5. Dissemination of Clinical Study  Data ......................................................89
10.1.6. Data Qualit y Assurance ............................................................................91
10.1.7. Source Documents ................................ ................................ .................... 92
10.1.8. Study  and Site Closure ..............................................................................92
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 810.1.9. Publication Policy.....................................................................................93
10.1.10. Sponsor’s Qualified Medical Personnel .................................................93
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................94
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -
up, and Reporting ......................................................................95
10.3.1. Definition of AE .......................................................................................95
10.3.2. Definition of an NDCMC
.........................................................................96
10.3.3. Definition of SAE
.....................................................................................96
10.3.4. Recording/Reporting and Follow- up of AEs and/or SAEs .......................98
10.3.5. Reporting of SAEs
..................................................................................101
10.5. Appendix 5: Genetics
..........................................................................................104
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ......105
10.7. Appendix 7: ECG Findings of Potential Clinical Conce rn.................................106
10.8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, 
Serious Adverse Events, and Device Deficiencies: Definition and Procedures 
for Recording, Evaluating, Follow -up, and Reporting ............................................[ADDRESS_847364] .................................................................................................107
10.8.3. Definition of Device Deficiency .............................................................108
10.8.4. Recording/Reporting and Follow
-up of AEs and/or SAEs and 
Device Deficiencies .......................................................................................109
10.8.5. Reporting of SAEs
..................................................................................111
10.8.6. Reporting of SADEs ...............................................................................112
10.9. Appendix 9: Country -Specific Requirements .....................................................112
10.10. Appendix 10: Abbreviations .............................................................................[ADDRESS_847365] OF TABLES
Table 1. Grading Scales for Local Reactions .........................................................51
Table 2. Grading Scales for Sy stemic Event Sy mptoms ........................................53
Table 3. Ranges for Fever ................................ ................................ ....................... 54
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
CT02- GSOP -RF04 6.0 Clinical Protocol Template P hase 1 2 3 4 (04 September 2018)
Page 9 
Table 5. Sample Size Required With Specified Power to Demonstrate NI 
Comparing the 20vPnC Group to the 13vPnC Group Based on 
Percentage of Participants With Prespecified Antibody  Levels 1 
Month After Dose 3 for Concomitant Antigens, With an NI  Margin 
of 10% .......................................................................................................76
Table 6. Sample Size Required With Specified Power to Demonstrate NI 
Based on Ratio of GMCs 1 Month After Dose 4 for Concomitant 
Antigens, With a 2
-Fold NI Margin .........................................................77
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 101.PROTOCOL SUMMARY
1.1.Synopsis
[COMPANY_007] is developi[INVESTIGATOR_007] a new 20- valent pneumococcal conjugate vaccine (20vPnC ) candidate to 
expand protection against pneumococcal disease bey ond that covered by  [CONTACT_634672]. 20vPnC has the same composition as 13- valent 
pneumococcal conjugate vaccine ( 13vPnC; Prevnar 13 ®/Prevenar 13® ), but contains an
additional [ADDRESS_847366] the pi[INVESTIGATOR_634660] y comparison of 20vPnC to the licensed pneumococcal conjugate vaccine, 
13vPnC, in infants to support licensure.
Approximately  2000 infants ≥42 to ≤98 day s of age at the time of consent, by  [CONTACT_404257](s)/legal guardian(s), will be enrolled into the study .  Participants will be randomized 
in a 1:1 ratio to receive ei ther 20vPnC or 13vPnC (control vaccine) at 2, 4, 6 ,and 12 to 
15 months of age (Doses 1 [Visit 1], 2 [Visit 2], 3 [Visit 3], and 4 [Visit 5], respectivel y).  
Participants will receive the same vaccine (either 20vPnC or 13vPnC) for all 4 doses.
Specific vac cines containing diphtheria, tetanus, acellular pertussis, hepatitis B, poliovirus , 
and Haemophilus influenzae type b (Hib) vaccine antigens will be administered
concomitantly  with Doses 1 to 3 (Visit 1, Visit 2 ,
and Visit 3) into a limb other than the site 
of 20vPnC or 13vPnC injection. Specific vaccines containing measles, mumps, rubella ,and 
varicella antigens will be administered concomitantly
 with Dose 4 (Visit 5) into a limb other 
than the site of 20vPnC or 13vPnC injection.
Local reactions (redness, swelling ,and pain at the injection site) ,systemic events (fever, 
decreased appetite, drowsiness/increased sleep ,and irritability ), and use of antipy retic/ pain 
medication will be prompted for and collected b y the participant’s parent(s)/legal guardian(s ) 
in an electronic diary  (e-diary ),device or application, from Day  1 through Day 7 after each 
vaccination (where Day  1 is the day  of vaccination).
Adverse events (AEs) will be collected from the time the participant’s parent(s)/legal 
guardian(s) provides informed consent through 1 month after Dose 3 (Visit 4) and from Dose 
4 (Visit 5) t hrough 1 month after Dose 4 (Visit 6). Serious adverse events (SAEs) and newl y 
diagnosed chronic medical conditions (NDCMCs) will be collected from informed consent 
through 6 months after Dose 4 (Visit 7).
Blood will be collected 1 month after Dose 3 (Visit 4), immediately  prior to Dose 4 (Visit 5) ,
and 1 month after Dose 4 (Visit 6) to assess immunogenicity .
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 11Objectives, Estimands, and Endpoints
Prim ary Safety Objective Estimands Prim ary Safety Endpoints
To describe the safety 
profile of 20vPnCIn participants receiving at least [ADDRESS_847367] and having safety 
data reported after any vaccination :
The percentage of participants 
reporting prompted local
reactions within 7 days after 
each vaccination in each group
The percentage of participants 
reporting prompted systemic 
events within 7 days after each 
vaccination in each group
The percentage of participants 
reporting AEs from Dose 1 to 
1month after Dose 3 in each 
group
The percentage of participants 
reporting AEs from Dose 4 to 
1month after Dose 4 in each 
group
The percentages of participants 
reporting SAEs up to 6 months 
after Dose 4 in each group
The percentages of participants 
reporting NDCMCs up to 6 
months after Dose 4 in each 
groupProm pted local 
reactions (redness, 
swelling ,and pain at 
the injection site)
Prom pted systemic 
events (fever, 
decreased appetite, 
drowsiness/increased 
sleep ,and irritability)
AEs
SAEs
NDCMCs
Prim ary Pneum ococcal 
Immunogenicity ObjectivesEstimands Prim ary Pneum ococcal 
Immunogenicity Endpoints
To demonstrate that the 
percentages of participants 
with predefined serotype-
specific immunoglobulin G 
(IgG)concentrations forthe 
13  serotypes in the 20vPnC 
group are noninferior to the
percentages for the 
corresponding serotypes in 
the13vPnC group at 
1month after Dose 3In participants in compliance with the 
key protocol criteria (evaluable 
participants) at 1 month after Dose 3:
For each of the 13 matched 
serotypes : difference in the 
percentages of participants with 
predefined serotype -specific IgG 
concentrations between the 20vPnC 
group and the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 12To demonstrate that the 
percentages of participants 
with predefined serotype-
specific IgG concentrations
forthe [ADDRESS_847368] percentage among 
the 13 serotypes in the
13vPnC group at 1 month 
after Dose 3In evaluable participants at 1 month after 
Dose 3:
For each of the 7 additional 
serotypes in 20vPnC: difference in 
the percentages of participants w ith 
predefined serotype -specific IgG 
concentrations, between the 20vPnC 
group and the lowest percentage of 
participants with predefined 
serotype -specific Ig G concentrations 
among the 13 serotypes from the 
13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG 
geometric mean 
concentrations ( GMCs )for
the 13 serotypes in the 
20vPnC group are 
noninferior to the GMCs for 
the corresponding serotypes 
in the 13vPnC group at 
1month after Dose 4In evaluable participants at 1 month after 
Dose 4:
For each of the 13 matched 
serotypes: geometric mean ratio 
(GMR )of serotype -specific IgG 
concentrations from the 20vPnC 
group to the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG 
GMCs forthe [ADDRESS_847369] IgG GMC among the 
13 serotypes in the 13vPnC 
group at 1month after 
Dose 4In evaluable participants at 1 month after 
Dose 4:
For each of the 7 additional 
serotypes in 20vPnC: GMR of 
serotype -specific IgG concentration 
from the 20vPnC group to that from 
the serotype with the low est IgG 
GMC among the 13 serotypes from 
the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
Prim ary Concomitant 
Immunogenicity ObjectiveEstimand Prim ary Concomitant 
Immunogenicity Endpoints
To demonstrate that the 
percentages of participants 
with prespecified antibody 
levels to specific 
concomitant vaccine 
antigens when given with 
20vPnC are noninferior to 
the corresponding 
percentages when the 
antigens are given with 
13vPnC at 1 month after 
Dose 3In evaluable participants who receive the 
appropriate concomitant vaccines:
Differences in percentages of 
participants with prespecified 
antibody levels to diphtheria toxoid, 
tetanus toxoid, pertussis antigens 
(pertussis toxin [ PT], filamentous 
hemagglutinin [ FHA ], pertactin 
[PRN ]), hepatitis B surface antigen
(HBsAg) ,poliovirus strains ,and 
Hib betw een the 20vPnC group and 
the 13vPnC group at 1 month after 
Dose 3Antibody levels to 
diphtheria toxoid, tetanus 
toxoid, and pertussis 
antigens (PT, FHA, PRN) 
Antibody levels to 
HBsAg
Antibody levels to 
poliovirus strains 
( types1, 2,and 3)
Antibody levels to Hib

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 13Key Secondary Pneum ococcal 
Immunogenicity ObjectivesEstimands Key Secondary 
Pneumococcal 
Immunogenicity Endpoints
To demonstrate that the 
serotype -specific IgG 
GMCs forthe 13 serotypes 
in the 20vPnC group are 
noninferior to the GMCs for 
the corresponding serotypes 
in the 13vPnC group at 
1month after Dose 3In participants in compliance with the 
key protocol criteri a (evaluable 
participants) at 1 month after Dose 3:
For each of the 13 matched 
serotypes: GMR of the serotype -
specific IgG concentrations from the 
20vPnC group to the 13vPnC groupPneumococcal
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG 
GMC sforthe [ADDRESS_847370] IgG GMC among the 
13 serotypes induced by [CONTACT_941] 
13vPnC group at 1 month 
after Dose 3In evaluable participants at 1 month aft er 
Dose 3:
For each of the 7 additional 
serotypes in 20vPnC: GMR of the 
serotype -specific IgG concentration 
from the 20vPnC group to that from 
the serotype with the low est IgG 
GMC among the 13 serotypes from 
the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
Secondary Pneumococcal 
Immunogenicity Objective Estimands Secondary Pneumococcal 
Immunogenicity Endpoints
To further describe the 
immunogenicity of 20vPnCIn evaluable participants at 1 month after 
Dose 3 and 1 month after Dose 4:
Serotype -specific opsonophagocytic 
activity ( OPA )geometric mean titers 
(GMTs )at 1 month after Dose 3, 
prior to Dose 4, and 1 month after 
Dose 4 in each group
In evaluable participants at 1 month after 
Dose 4:
For each of the serotypes in 2 0vPnC: 
percentages of participants with the 
predefined serotype -specific IgG 
concentration in each group
In evaluable participants:
Geom etric mean fold rises 
(GMFRs) in serotype -specific 
IgG concentrations from 
1month after Dose 3 to before 
Dose 4, from before Dose 4 to 
1month after Dose 4, and from 
1 month after Dose 3 to 1 month 
after Dose 4 in each groupPneumococcal 
serotype -specific OPA 
titers
Pneumococcal 
serotype -specific IgG 
concentrations

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 14Secondary Concom itant 
Immunogenicity Objective sEstimands Secondary Concom itant 
Immunogenicity Endpoints
To further describe the 
immune responses induced 
by [CONTACT_634673] 
20vPnC or 13vPnCIn evaluable participants who receive the 
appropriate concomitant vaccines:
Differences in percentages of 
participants with alternative 
prespecified antibody levels to Hib
betw een the 20vPnC group and the 
13vPnC group at 1 month after 
Dose 3Antibody levels to Hib
To demonstrate that GMCs 
tospecific concomitant 
vaccine antigens when
given with 20vPnC are 
noninferior to the 
corresponding GMCs when 
the antigens are given with 
13vPnC at 1 month after 
Dose 4GMRs of antibody levels to measles, 
mumps, rubella ,and varicella 
viruses from the 20vPnC group to 
the 13vPnC group at 1 month after 
Dose 4Antibody levels to 
measles, mumps, rubella,
and varicella viruses
Number of Participants
Approximately  2000 participants will be enrolled to achieve a target of 1600 evaluable 
participants (800 in each vaccine group) at the time point 1 month after Dose 3 (Visit 4).
Duration of Participation for Each Participant
Each participant will participate in the study  for approximately  16to 19 months.
 
 
  
Statistical Methods
Safety  Objectives
The primary  safet y objective will be evaluated b y descri ptive summary  statistics for local 
reactions, s ystemic events, and AEs, including SAEs and NDCMCs ,for each vaccine group.  
A 3-tier approach will be used to summarize AEs.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 15Pneumococcal Immunogenicity  Objectives
The primary  pneumococcal immunogenicity  objectives will be evaluated by  [CONTACT_634674] 20vPnC to 13vPnC based on serotype -specific IgG 
results. At 1 month after Dose 3, n oninferiorit y for a serot ype will be declared if the lower 
bound of the 2- sided 95% confidence interval ( CI)for the between -group difference in 
percent ageof participants with a predefined seroty pe-specific IgG concentration level
(20vPnC – 13vPnC) is greater than –10% (10% noninferiority  margin) .
 
 
For t heother primary pneumococcal immunogenicity objective stoevaluat e the
pneumococcal immune response a t 1 month after Dose 4
, noninferiorit y for a serot ype at 
1month after Dose 4 will be declared if the lower bound of the 2- sided 95% CI  for the IgG 
GMR of the 20vPnC group relative to the 13vPnC group is greater than 0.5 (2 -fold 
noninferiority  margin).
 
 
 
 
 
 
 
Additionally , serot ype-specific IgG GMCs, OPA GMTs, IgG  GMFR s,  
 
, will be provided for the specified time points for each vaccine group to provide further 
characterization of the immune r esponse.
CCI
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 16Concomitant I mmunogenicity  Objectives
The primary  concomitant immunogenicit y objective will also be evaluated by [CONTACT_634675] y of the 20vPnC group to the 13vPnC group . At the visit 
1month after Dose 3 (Visit 4), noni nferiority  for each antigen will be declared if the lower 
bound of the 2- sided 95% CI  for the difference in percentages (20vPnC – 13vPnC) of 
participants with prespecified antibody  levels to diphtheria toxoid, tetanus toxoid, pertussis 
antigens (PT, FHA, P RN), HBsAg , poliovirus strains ,and Hib is greater than –10%
(10% noninferiority  margin) . 
 
1.2.Schema
Not applicable.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 171.3.Schedule of Activi ties (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the Study  Assessments and Procedures section of 
the protocol for detailed information on each procedure and assessment required for compliance with the protocol.
The investigator may  schedule visits (unplanned visits) in addit ion to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant.
Visit Number 1 2 3 4 5 6 7
Visit Description Dose 1 Visit Dose 2 Visit Dose 3 Visit Dose 3 
Follow -up VisitDose 4
VisitDose 4
Follow -upVisitDose 4
6-Month Visit
Visit Window (Days) Day [ADDRESS_847371] vaccines received during 
pregnancy and intrapartum antibiotics
(ifavailable)X
Record nonstudy vaccinations X X X X X X
Record concomitant medicationsdX X X X X X X
Obtain prevaccination rectal temperature X X X X
Revie w inclusion and exclusion criteria X
Revie w temporary  delay criteria X X X X X X
Revie w continued eligibility X X X X X
Assign randomization number X
Obtain ~[ADDRESS_847372]
(20vPnC or 13vPnC)fX X X X
Administer specific concomitant vaccines 
as applicable for the visitXgXgXgXh

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 18Visit Number 1 2 3 4 5 6 7
Visit Description Dose 1 Visit Dose 2 Visit Dose 3 Visit Dose 3 
Follow -up VisitDose 4
VisitDose 4
Follow -upVisitDose 4
6-Month Visit
Visit Window (Days) Day [ADDRESS_847373] X
Provide parent(s)/legal guardian(s) with an 
e-diary, thermometer ,and measuring 
device and instruct to collect prompted 
local reactions and systemic events until 
7days after vaccinationiX X X X
Revie w and/or collect e- diary 
(ifapplicable)jX X X X
Record and report adverse events X------------------------------------------------------------ X X------------------- X

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 19Visit Number 1 2 3 4 5 6 7
Visit Description Dose 1 Visit Dose 2 Visit Dose 3 Visit Dose 3 
Follow -up VisitDose 4
VisitDose 4
Follow -upVisitDose 4
6-Month Visit
Visit Window (Days) Day [ADDRESS_847374] and report SAEs and NDCMCsk,lX--------------------------------------------------------------------------------------------------------------------------- X
Abbreviations: e -diary = electronic diary; IRT = interactive response technology; NDCMC = newly diagnosed chronic medical condition.
a.Per Amendment 2: The last day to be eligible for Dose 4 (Visit 5) is [ADDRESS_847375] not received Dose 4 by [CONTACT_634676] ( Section 7).
b.Per Amendment 2: The w indow for Visit [ADDRESS_847376] information for Visit 6 by [CONTACT_756].
c
.Per Amendment 2 : The w indow for Visit [ADDRESS_847377] Visit 5 (receive Dose 4) after 18 Feb2022: 
Visit 5 performed after 18 Feb2022 through 14Mar 2022 :the window  is 168 to 196 days after Visit 5, or until 02Sep2022, whichever is earlier .
Visit 5 performed on 15 Mar 2022 through 01Apr2022: the window  is 145 to 168 days after Visit 5, or until 02 Sep2022, w hichever is earlier.
Visit 5 performed on 02 Apr2022 through 20Apr2022: the window  is [ADDRESS_847378] only concomitant medications used to treat SAEs and NDCMCs.
e.Blood sample will be collected prior to vaccination.
f.Remind the participant’s parent(s)/legal guardian(s) that the use of prophylactic antipyretic/pain medication, while permitted, is not recommended on the 
day of investigational product administration (before or after vaccination).
g.Specific concomitant vaccines containing diphtheria, tetanus, acellular per tussis, hepatitis B, polio virus , and Haem ophilus influenzae type bvaccine 
antigens will be administered with Doses 1 through 3 into a limb other than the site of 20vPnC or 13vPnC injection .  Rotavirus and influenza vaccine s
may also be administered with the specific concomitant vaccines during the appropriate study visits (if applicable).  See Section 6.5for detai ls on 
prohibited and permitted concomitant vaccines .
h
.Specific concomitant vaccines containing measles, mumps, rubella ,and varicella antigens will be administered with Dose 4 into a limb other than the site 
of 20vPnC or 13vPnC injection .Influenza vaccine may also be administered with the specific concomitant vaccines during the study visit.  
SeeSection 6.5for details on prohibited and permitted concomitant vaccines .
i.The participant’s parent(s)/legal guardian(s) will record prompted local reactions and systemic events in an e -diary for the 7 days following each dose of
20vPnC or 13vPnC. Use of antipyretic/pain medications will also be prompted for and collected daily in an e -diary for 7 days after vaccination. The 
participant’s parent(s)/legal guardian(s) w ill be instructed to contact [CONTACT_634677] s or sw elling>14 caliper units, 
severe pain at the 20vPnC or 13vPnC injection site, or a fever >104.0°F (>40.0°C) or has an emergency room visit or hospi[INVESTIGATOR_18543]
j.Designated site staff will review e -diary data online at frequent intervals (daily is opt imal) for the 7 days following each dose of 20vPnC or 13vPnC to 
evaluate participant compliance and as part of the ongoing safety review.
k. An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long -lasting in its effects.
l.If the parent(s)/legal guardian(s) consents, participants withdrawn from the study will receive a [ADDRESS_847379] dose of 
study vaccination for collection of any SAEs and NDC MCs.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 20Amendment 2: Summary of the Modification sto the SoA Table
Visit 5 : The upper limit for the Visit 5 window is no longer based on age.  Instead, eligibility  
for Visit 5 ends after 20 Apr2022.
Visit 6: The blood draw at this visit will be performed through 06 May 2022; after that date, 
blood will not be collected at Visit 6, and investigator sites have the option of collecting the 
information for Visit 6 by [CONTACT_756] (the window between Visit 5 and Visi t 6 remains the 
same, 28 to 42 day s after Visit 5).
Visit 7: The last day  to complete this visit is [ADDRESS_847380] Visit 5 (receive Dose 4) after 18 Feb2022:
For a participant with Visit 5 performed after 18 Feb2022 through 14 Mar 2022, the 
window is 168 to 196 days after Visit 5, or until 02
Sep2022, whichever is earlier.
For a participant with Visit 5 performed on 15 Mar 2022 through 01 Apr2022, the 
window is 145 to 168 days after Vi sit 5, or until 02 Sep2022, whichever is earlier.
For a participant with Visit 5 performed on 02 Apr2022 through 20 Apr2022, the 
window is 126 to 145 days after Visit 5, or until 02 Sep 2022, whichever is earlier.
2.INTRODUCTION
Pneumococcal Disease
Streptococcus pneumoniae are gram -positive encapsulated cocci that are a leading cause of 
bacteremia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and continue to 
be a major global public health concern.1,2,3Serious pneumococcal disease may  occur at an y 
age; however, children <5 years and adults ≥ 65 years of age are at particularly  increased 
risk.4  Individuals with certain comorbidities and immunocompromising conditions are also 
at risk, especiall y persons with chronic heart, lung, liver, and renal disease, as well as those 
who are functionall y asplenic.  The global burden of pneumococcal disease has been 
substantially  impacted b y pneumococcal conjugate vaccines.  S pneumoniae caused an 
estimated 14.5 million cases of serious disease and 826,0 00 deaths annuall y in children 
<5years of age prior to introduction of pneumococcal conjugate vaccines.2  It has been 
estimated that in 2015, several years following introduction of pneumococcal conjugate 
vaccines into the national infant immunization programs of more than 100 countries, the 
global disease burden had declined, but S pneumoniae still accounted for 2.6 million cases of 
severe pneumococcal disease, 332,000 deaths in children <5 y ears of age, and 11% of deaths
in children between the ages of 1 and 5 years.5
The overall invasive pneum ococcal disease (I PD) burden was estimated in [ADDRESS_847381] 
decreased approximately  90% in the population <5 y ears of age in the [LOCATION_002] since the 
introduction of pneumococcal conjugate vaccines; however, there was a slight increase in the 
proportions of IPD cases associated with hospi[INVESTIGATOR_059] (63% to 71%), and the I PD case 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 21fatality rate was also slightly  but statistically  significantly  increased (2% to 3%) in that age 
group.6This is due to the decrease in disease due to the serot ypes in 7-valent p neumococcal 
conjugate vaccine ( 7vPnC
; Prevnar®) and 13vPnC.  However, disease due to seroty pes not 
covered b y those vaccines remains, and causes significant morbidity  and mortality . National 
IPD surveillance data in England and Wales for the epi[INVESTIGATOR_634661] 2016 -2017, 
approximately  10 y ears after the introduction of 7vPnC in the national infant immunization 
program and 6 years after the introduction of 13vPnC, showed the overall incidence of I PD 
was 9.87 per 100,000 population, with an incidence of 13 .90 per 100,000 population <2 y ears 
of age.7  The data for England and Wales are consistent with the patterns observed in data 
from the European Union (EU) for 2017, which showed an overall IPD incidence of 
6.2
cases per 100,000 population, with an inciden ce of 14.5 per 100,000 infants under 1 year 
of age.8  Pediatric surveillance studies conducted between 2007 and 2013 in 8 US children’s 
hospi[INVESTIGATOR_600], and between 1997 and 2010 in a referral center in Utah, found case fatalit y rates of 
10% and 13% with pneumoc occal meningitis, respectivel y.  These studies also found that 
between 52% and 63% of children surviving pneumococcal meningitis experience neurologic 
sequelae.9,10
  More recent pediatric surveillance conducted between 2014 and 2017 in 8 US 
children’s hospi [INVESTIGATOR_634662] 13vPnC introduction in 2010 showed that 76.1% of residual 
IPD was caused b y non -13vPnC seroty pe isolates.11  Seroty pes 10A, 12F, 15B/15C, 22F ,and 
33F accounted for 36% of isolates causing IPD.  The most common clinical presentations of 
IPD due to non -13vPnC seroty pes included bacteremia (49.6%), meningitis (19.1%), and 
pneumonia (18.8%).  These data demonstrate the continued need for expanded serot ype 
coverage.
Surveillance studies conducted in 2010 -2012 by  [CONTACT_634678]
d 
Prevention (CDC) found that S pneumoniae remains among the most common pathogens
identified in community -acquired pneumonia (CAP) requiring hospi[INVESTIGATOR_407367].12,13Itwas the most common bacterial cause in ch ildren 
<2years of age, even in the setting of a 43% reduction in CAP hospi[INVESTIGATOR_407368] 1997- 1999 and 2007 -2009, due to the introduction to 7vPnC .12,14
Surveillance reported in 2017 by  [CONTACT_407387] 
(ECDC) showed that among cases of IPD for which the clinical presentation was known 
across all age groups, bacteremic pneumonia was reported in 42% o f cases. The most 
common clinical presentations in children <5 years of age were septicemia and bacteremic 
pneumonia (1
-4 year olds), and meningitis (<1 y ear olds).[ADDRESS_847382] that 
Spneumoniae remains an important cause of serious disease in the [LOCATION_002] and 
worldwide.
AOM is a common childhood illness, with 2011 visit rates of 0.82 and 0.81 visits per 
AOM/child
-year in children <2 years of age and 2 to 6 y ears of age, respectively , and 
represents a significant medical burden.15  S pneumoniae is one of the common bacterial 
causes of AOM , and accounted for an estimated 850,000 outpatient and 125,000 emergency  
room visits in the [LOCATION_002] in 2004 in children <5 years of age, representing a significant 
burden on the healthcare sy stem.3While AOM is generall y not considered a serious disease, 
it does carry  the risk of more serious complications.  These complications can range from the 
development of chronic or recurrent otitis media necessitatin g surgical intervention 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 22(tympanostom y tube placement), and accompanied by  [CONTACT_407388] s, to invasive extension leading to mastoiditis and 
meningitis.
Although the introduction of pneumococcal conjugate vacc ines into the [LOCATION_002] and 
other national infant immunization programs has brought about substantial reductions in the 
various manifestations of pneumococcal disease in pediatric (infants and children) 
populations, a substantial burden of pneumococcal disease remains. Serotypes not included 
in existing vaccines continue to contribute significantly  to morbidity  and mortality .
Vaccines to Prevent Pneumococcal Disease
Pneumococcal Polysaccharide Vaccines
The poly saccharide capsule has been identified as an important virulence factor for this 
pathogen.  While more than [ADDRESS_847383] the specific 
seroty pe bind to the capsule and promote complement -mediated opsonophagocy tic killing 
and clearance of the organism.18  Pneumococcal disease can be prevented with 
polysaccharide -based vaccines that induce anti body  responses with functional 
(opsonophagocy tic) activity  and target the capsular serot ypes responsible for disease.[ADDRESS_847384] been licensed since the 1970s.  One such 
vaccine, the 23 -valent pneumococcal poly saccharide vaccine (PPSV23), has been licensed in 
the [LOCATION_002] since 1983.20
,21  PPSV23 contains capsular pol ysaccharides for 
23seroty pes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 
20, 22F, 23F, and 33F).  Pneumococcal vaccine s containing free pol ysaccharides such as 
PPSV23 elicit a T -cell–independent immune response.  Unconjugated pol ysaccharide 
vaccines do not induce robust responses in certain populations (eg, immunocompromised 
persons, and children <2 years of age), nor do they generate immunologic memory , so that 
their protective effect wanes over 2 to 5 years.4,21,22
,23  Moreover, their ability  to prevent 
nonbacteremic pneumonia, CAP, and AOM is limited or lacking.19
,23,24,25,26  In addition, 
polysaccharide vaccines do not reduce vaccine -type (VT) nasophary ngeal carriage, which is 
important for herd immunity .26  PPSV23 is not recommended for children <2 y ears of age 
and only  recommended in children >2 years of age who are at high risk for IPD to provide 
some degree of protection from disease caused b y serotypes not covered b y existing 
pneumococcal conjugate vaccines.19
Pneumococcal Polysaccharide C onjugate Vaccines
Pneumococcal conjugate vaccines contain poly saccharides that are covalently  linked 
(conjugated) to an immunogenic protein.  This modification results in T -cell–dependent 
immune responses, which have been shown to be protective in young children, older adul ts, 
and populations with high -risk conditions.22,[ADDRESS_847385] pneumococcal conjugate 
vaccine to be licensed (2000) and was indicated for prevention of pneumococcal disease in 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 23infants and young children on the basis of efficacy studies.  7vPnC contained capsular 
polysaccharide conjugates for 7 pneumococcal seroty pes ( 4, 6B, 9V, 14, 18C, 19F, and 23F), 
each covalentl y linked to cross -reactiv e material 197 (CRM 197), a nontoxic variant of
diphtheria toxin.  These 7 seroty pes were responsible for approximately  80% to 90% of IPD 
in children <5 years of age in the [LOCATION_002] and approximately  60% to 80% of IPD in the 
same age group in Europe at that time (1998- 2000).28,29,30,31,[ADDRESS_847386] 
clinically /radiographically  defined pneumonia.[ADDRESS_847387] effects, 
with a 92% reduction of 7vPnC VT I PDin older adults ≥ [ADDRESS_847388] CAP due to seroty pes contained in 13vPnC in adults 
65years of age and older.42  13vPnC has replaced 7vPnC and is licen sed in the [LOCATION_002] 
and man y other countries, with national recommendations for use in children and older 
adults.43
,44,45,46  It has also been prequalified b y the World Health Organization (WHO) for 
use in national infant immunization programs in lower - and middle -income countries.47,[ADDRESS_847389] 13vPnC VT
IPDin the vaccinated population.49,50,51
Development of 20vPnC
The 20vPnC candidate is modeled after 7vPnC and 13vPnC, and contains poly saccharides of 
capsular serot ypes of S pneumoniae , each covalently  linked to CRM 197. The amount of
polysaccharide (2.2 µg/dose) selected for each new serot ype ( 8, 10A, 11A, 12F, 15B, 22F, 
and 33F) contained in the 20vPnC candidate mirrors the approach taken for the addition of 
the 6 new serot ypes when developi[INVESTIGATOR_007] 13vPnC.  The 20vPnC candidate contains the same 
components as 13vPnC, including the 13 pol ysaccharide conjugates, excipi[INVESTIGATOR_840] 
(poly sorbate 80, succinate buffer, sodium chloride), and aluminum phosphate, in addition to 
the 7 new pol ysaccharide conjugates.  Additional epi[INVESTIGATOR_634663] 7 seroty pes and 
the preclinical program are described in the 20vPnC investigator’s brochure (IB).  The 
vaccine is being developed for use in pediatric and adult populations.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 242.1.Study Rationale
 
 
  The 
targeted age of the population for this study , infants ≥42 to ≤98 day s of age, has been 
selected as the routine ly recommended vaccination schedule for pneumococcal conjugate 
vaccines andother vaccines in infants ,startingat approximately  2 months of age.   The 
participants will be administered either 20vPnC or 13vPnC at 2, 4, 6, and 12 to 15 months of 
age.  Data w ill also be generated on key  routine pediatric vaccines given concomitantly  with 
20vPnC or 13vPnC.
Amendment 2 is being implemented to complete the vaccination schedule in a timely  manner 
as all participants are age -eligible for their final dose (Dose 4) a s of the amendment date. 
There is no benefit to the participant to delay  completion of the series. Delay ing vaccination 
andin-person study  visits later in the trial also carries a risk of additional delay sin 
vaccination and exposure risks that may  occur with a potential resurgence of coronavirus
disease in the near future.  
 
 
 
 
The modifications in this amendment impact only  a very small overall 
proportion 
of participants who have not yet received Dose 4, and do not adversel y affect the
safet y, scientific integrity, or management of the study .
2.2.Background
20vPnC is being developed to further expand protection against the global burden of 
vaccine -preventable pneumococcal disease in children and adults over that of 13vPnC.  
20vPnC contains the seroty pes present in 13 vPnC , and 7 new seroty pes (8, 10A, 11A, 12F, 
15B, 22F, and 33F) individually  conjugated to CRM 197.As noted above, 20vPnC uses the
same platform and contains the same excipi[INVESTIGATOR_126496] 13vPnC.  These 7 additional serot ypes 
were sel ected based on their relative prevalence as a cause of IPD, their generalized 
geographic distribution, and other factors that would support inclusion, such as the presence 
of antibiotic resistance (11A, 15B), association with outbreaks (8, 12F) ,and greater disease 
severit y (eg, meningitis, mortality ) (10A, 11A, 22F).52,53,54,55,56,57,58,59,60,61,62,[ADDRESS_847390] a long -standing association with serious pneumococcal disease and are 
responsible for a substantial burden of remaining pneumococcal d isease.  The incidence of 
IPD due to these 7 serot ypes in children <[ADDRESS_847391] several y ears, and these serot ypes cause a significant amount 
of IPD in children.64,65,66,67,68,69,70  These 7 se rotypes contribute to the burden of IPD in the 
[LOCATION_002] and elsewhere. It is estimated that between 2015 and 2016, these 7 serot ypes 
accounted for 34% to 39% of IPD in children in the U nited States.71In the EU, 
according to 
the ECDC annual I PD epi[INVESTIGATOR_634664] ,in 2017, approximately  75% of cases of IPD 
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 25in children <5 years of age were caused by  a seroty pe not in 13vPnC, increased from 63% in 
2013. Five of the [ADDRESS_847392] common in children in this age 
group.8
A meta -analy sis of seroty pes causing IPD in children <[ADDRESS_847393] introduced higher -valent pneumococcal conjugate vaccines (such as 13vPnC ) 
showed that, overall, these 7 serot ypes accounted for approximately  70% of disease not due 
to the 13vPnC vaccine types.66
2.2.1. Clinical Overview
Safety  and immunogeni city data from a 20vPnC Phase 1 study  (B7471001) conducted in 
healthy adults 18 through 49 years of age demonstrated that the vaccine induces immune 
responses to the 20 vaccine serotypes and has a safety profile consistent with other 
pneumococcal conjugate vaccines.  These data supported clinical development in other 
populations, including pediatrics.
A Phase 2 study  (B7471003) of 20vPnC in healthy infants ≥42 to ≤98 day s of age has been 
conducted. The stud y randomized 460 US participants to receive either blinded 20vPnC or 
13vPnC. Safety  and immunogenicit y data are available from the stud
y.  20vPnC was well 
tolerated in the infants and the safet y profile was similar to that of the 13vPnC group in the 
study  and consistent with other pneumococcal conjugate vaccines. Immune responses (either 
IgG GMCs or percent ages of participants meeting a predefined IgG concentration) after 
3 doses of 20vPnC were similar to those in the 13vPnC group. These data support continued 
development of 20vPnC in a pediatric population.
2.3.Benefit/Risk Assessment
13vPnC is a licensed vaccine and the most common AEs noted in children <5 y ears of age 
after vaccination are primarily related to local reactions (injection site pain or tenderness, 
redness ,and swelling) and sy stemic events (fever, irritability , decreased appetite, and 
increased sleep).
The 20vPnC investigational product contains the same components and excipi[INVESTIGATOR_126496] 
13vPnC, but also contains the poly saccharide conjugates for the 7 additional pneumococcal
seroty pes.  Thus, the AE profile of 20vPnC is expected to be similar to 13vPnC, but AEs may  
be different with the investigational 20vPnC.
In a randomized, active- controlled ,double -blind study  with a 2 -arm parallel design 
(B7471003), 20vPnC was administer ed to 460 infants ≥42 to ≤[ADDRESS_847394] common AEs after 20vPnC 
administration were local reactions ( pain, redness, and swelling at the injection site) and 
systemic events (irritability , drowsiness/increased sleep, and decreased appetite).
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 26As with any  vaccine, an allergic reaction can occur. The allergic reaction can vary  from skin 
rash to swelling of the face or lips, wheezing , and/or shortness of breath. A severe allergic 
reaction (anaph ylactic shock, collapse ,or shock- like state [hy potonic -hyporesponsive 
epi[INVESTIGATOR_1865]]) may  also occur. There may  also be additional risks related to the vaccines 
administered in the study that are not known at this time.
Diphtheria, tetanus, and acellular pertussis (DTaP) combination vaccine is a licensed vaccine 
and the most common AEs seen after vaccination include local reactions (injection site pain, 
redness ,and swelling )and sy stemic events (fever, drowsiness/increased sleep, 
irritability /fussiness, and loss of appetite ).
Hib vaccine is a licensed vaccine and the most common AEs seen after vaccination include 
local reactions (injection site pain/tenderness, redness, and s welling) and s ystemic events 
(irritability , drowsiness/decreased activity , fever, and decreased appetite).
Measles, m umps, and rubella vaccine (MMR) is a license dvaccine and the most common 
AEs after vaccination include local reactions (injection site ten derness, pain, redness ,and 
swelling) and s ystemic events (fever and irritability ).
Varicella vaccine is a licensed vaccine and the most common AEs include local reactions 
(injection site pain, swelling, redness, and rash) and fever.
Risks that may  be associated with study  procedures include risks from blood draws, 
including pain, swelling, bruising, and infection where blood is taken.
Safety  assessments described in the protocol and ongoing review of safet y data b y the 
investigator and sponsor study  team w ill serve to monitor and mitigate these risks.  
 
13vPnC is approved for the prevention of pneumococcal disease due to the seroty pes in the 
vaccine, and may  provide a clinical benefit to those receiving it.
DTaP combination vaccine is approved for the prevention of diphtheria, tetanus, pertussis, 
diseases due to subtypes of hepatitis B virus ,and poliomy elitis, and may  provide a clinical 
benefit to those receiving it.
Hib vaccine is approved for the prevention of invasive disease caused by  [CONTACT_634679] a clinical benefit to those receiving it.
MMR is approved for the prevention of measles, mumps, and rubella and may  provide a 
clinic al benefit to those receiving it.
Varicella vaccine is approved for the prevention of varicella and may  provide a clinical 
benefit to those receiving it.
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847395] pneumococcal disease will be similar to 
13vPnC . If 20vPnC is successful in Phase 3 studies, and approved, it is anticipated to 
provide a public health benefit b y reducing the burden of pneumococcal disease (invasive 
and noninvasive) due to vaccine serot ypes.
[COMPANY_007] considers that the available information from S tudy B7471003 with 20vPnC, the 
available safet y profile of similar pneumococcal conjugate vaccines (ie, Prevnar and 
Prevnar 13), and the limited risks from study  procedures support a favorable benefit -risk 
profile for 20vPnC and this study .
More detailed i nformation about the known and expected benefits and risks and reasonabl y 
expected AEs of 20vPnC may  be found in the IB, which is the single reference safet y 
document (SRSD) for this study . The SRSD for the 13vPnC control vaccine is the US 
package insert. The SRSDs for the specified concomitant vaccines are the US package 
inserts.
3.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Prim ary Safety Objective Estimands Prim ary Safety Endpoints
To describe the safety 
profile of 20vPnCIn participants receiving at least [ADDRESS_847396] and having safety 
data reported after any vaccination: 
The percentage of participants 
reporting prompted local 
reactions within 7 days after 
each vaccination in each group
The percentag e of participants 
reporting prompted systemic 
events within 7 days after each 
vaccination in each group
The percentage of participants 
reporting AEs from Dose 1 to 
1month after Dose 3 in each 
group
The percentage of participants 
reporting AEs from Dose 4 to 
1month after Dose 4 in each 
group
The percentages of participants 
reporting SAEs up to 6 months 
after Dose 4 in each group
The percentages of participants 
reporting NDCMCs up to 6 
months after Dose 4 in each 
groupProm pted local 
reactions (redness, 
swelling ,and pain at 
the injection site)
Prom pted systemic 
events (fever, 
decreased appetite, 
drowsiness/increased 
sleep ,and irritability)
AEs
SAEs
NDCMCs
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 28Prim ary Pneum ococcal 
Immunogenicity ObjectivesEstimands Prim ary Pneum ococcal 
Immunogenicity Endpoints
To demonstrate that the 
percentages of participants 
with predefined serotype-
specific IgG concentrations
forthe 13 serotypes in the 
20vPnC group are 
noninferior to the 
percentages for the 
corresponding serotype sin 
the 13vPnC group at 1 
month after Dose 3In participants in compliance with the 
key protocol criteria (evaluable 
participants) at 1 month after Dose 3:
For each of the 13 matched 
serotypes: difference in the 
percentages of participants with 
predefined serotype -specific IgG 
concentr ations between the 20vPnC 
group and the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
percentages of participants 
with predefined serotype-
specific IgG concentrations
forthe 7 additional 
serotypes in the 20vPnC
group are noninferior to the 
lowestpercentage among
the 13 serotypes in the 
13vPnC group at 1 month 
after Dose 3In evaluable participants at 1 month after 
Dose 3:
For each of the 7 additional 
serotypes in 20vPnC : difference in 
the percentages of participants w ith 
predefined serotype -specific IgG 
concentrations, between the 20vPnC 
group and the lowest percentage of 
participants with predefined 
serotype -specific IgG concentrations 
among the 13 serotypes from the 
13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG 
GMCs forthe 13 serotypes 
in the 20vPnC group are 
noninferior to the GMCs for 
the corresponding serotypes 
in the 13vPnC group at 1 
month after Dose 4In evaluable participants at 1 month after 
Dose 4:
For each of the 13 matched 
serotypes: GMR of serotype -specific 
IgG concentrations from the 20vPnC 
group to the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG 
GMCs for the [ADDRESS_847397] IgG GMC among the 
13 serotypes in the 13vPnC 
group at 1 month after 
Dose 4In evaluable participants at 1 month after 
Dose 4:
For each of the 7 additional 
serotypes in 20vPnC: GMR of 
serotype -specific IgG concentration 
from the 20vPnC group to that from 
the serotype with the low est IgG 
GMC among the13 serotypes from 
the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentrat ion
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 29Prim ary Concomitant 
Immunogenicity ObjectiveEstimand Prim ary Concomitant 
Immunogenicity Endpoints
To demonstrate that 
percentages of participants 
with prespecified antibody 
levels to specific 
concomitant vaccine 
antigens when given with 
20vPnC are noninferior to 
the corresponding 
percentages when the 
antigens are given with 
13vPnC at 1 month after 
Dose 3In evaluable participants who receive the 
appropriate concomitant vaccines:
Differences in percentages of 
participants with prespecified 
antibody levels to diphtheria toxoid, 
tetanus toxoid, pertussis antigens 
(PT, FHA, PRN), HBsAg , 
poliovirus strains ,and Hib between 
the 20vPnC group and the 13vPnC 
group at 1 month after Dose 3Antibody levels to 
diphtheria toxoid, tetanus 
toxoid, and pertussis 
antigens (PT, FHA, PRN) 
Antibody levels to 
HBsAg
Antibody levels to 
poliovirus strains 
(types1, 2,and 3)
Antibody levels to Hib
Key Secondary Pneum ococcal 
Immunogenicity ObjectivesEstimands Key Secondary 
Pneumococcal 
Immunogenicity Endpoints
To demonstrate that the 
serotype -specific IgG 
GMCs forthe 13 serotypes 
in the 20vPnC group are 
noninferior to the GMCs for 
the corresponding serotypes 
in the 13vPnC group at 1 
month after Dose 3In participants in compliance with the 
key protocol criteria (evaluable 
participants) at 1 month after Dose 3:
For each of the 13 matched 
serotypes: GMR of serotype -specific 
IgG concentrations from the 20vPnC 
group to the 13vPnC groupPneumococcal 
serotype -specific IgG 
concentration
To demonstrate that the 
serotype -specific IgG GMC
forthe [ADDRESS_847398] IgG GMC among the 
13 serotypes in the 13vPnC 
group at 1 month after 
Dose 3In evaluable participants at 1 month after 
Dose 3:
For each of the 7 additional 
serotypes in 20vPnC: GMR of 
serotype -specific IgG concentration 
from the 20vPnC group to that from 
the serotype with the low est IgG 
GMC among the 13 serotypes from 
the 13vPnC groupPneumo coccal 
serotype -specific IgG 
concentration
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 30Secondary Pneumococcal 
Immunogenicity Objective Estimands Secondary Pneumococcal 
Immunogenicity Endpoints
To further describe the 
immunogenicity of 20vPnCIn evaluable participants at 1 month after 
Dose 3 and 1 month after Dose 4:
Serotype -specific OPA GMTs at 
1month after Dose 3, prior to Dose 
4,and 1 month after Dose 4 in each 
group
In evaluable participants at 1 month after 
Dose 4:
For each of the serotypes in 20vPnC: 
percentages of participants with the 
predefined serotype -specific IgG 
concentration in each group
In evaluable participants:
GMFRs in serotype- specific IgG 
concentrations from 1 month after 
Dose 3 to before Dose 4, from 
before Dose 4 to 1 month after Dose 
4, and from 1 month after Dose 3 to 
1 month after Dose 4 in each groupPneumococcal 
serotype -specific OPA 
titers
Pneumococcal 
serotype -specific IgG 
concentrations 
Secondary Concom itant 
Immunogenicity Objective sEstimands Secondary Concom itant 
Immunogenicity Endpoints
To further describe the 
immune responses induced 
by [CONTACT_634673] 
20vPnC or 13vPnCIn evaluable participants who receive the 
appropriate concomitant vaccines:
Differences in percentages of 
participants with alternative 
prespecified antibody levels to Hib
betw een the 20vPnC group and the 
13vPnC group at 1 month after 
Dose 3Antibody levels to Hib
To demonstrate that GMCs 
to specific concomitant 
vaccine antigens when 
given with 20vPnC are 
noninferior to the 
corresponding GMCs when 
the antigens are given with 
13vPnC at 1 month after 
Dose 4GMRs of antibody levels to measles, 
mumps, rubella ,and varicella 
viruses from the 20vPnC group to 
the 13vPnC group at 1 month after 
Dose 4Antibody levels to 
measles, mumps, rubella,
and varicella viruses
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 31  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
rs
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847399] the pi[INVESTIGATOR_634660] y comparison of 20vPnC to the licensed pneumococcal conjugate vaccine, 
13vPnC, in infants .  Data will also b e generated on key  routine pediatric 
vaccines given concomitantly  with 20vPnC. 13vPnC will serve as an active comparator.
Approximately  2000 infants ≥42 to ≤98 day s of age at the time of consent, by  [CONTACT_404257](s)/legal guardian(s), will be enrolled.  Pa rticipants will be randomized in a 1:1 ratio to 
receive either 20vPnC or 13vPnC (control vaccine) at 2, 4, 6 ,and 12 to 15 months of age 
(Doses 1, 2, 3, and 4, respectivel y)by [CONTACT_3725]-based randomization .  Participants will receive the 
same vaccine (20vPnC o r 13vPnC) for all 4 doses.
On Day  1 (Visit 1, Dose 1 vaccination) of the study , participants will be assessed for 
eligibility  and information collected, including medical history , vaccine history , and maternal 
immunization (vaccines administered during pre gnancy ) history  (if available).
At Visit 1, participants will be randomized and receive Dose 1 of 20vPnC or 13vPnC. 
20vPnC and 13vPnC will be identical in appearance and will be prepared and administered 
by a qualified site staff member or designee. Spec ific concomitant vaccines containing 
diphtheria, tetanus, acellular pertussis, hepatitis B virus , polio virus , and Hib antigens will 
also be administered at this visit and at Visits 2 and 3. Participants will be observed for 
30 minutes after vaccination an d any reactions occurring during that time will be recorded as 
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 33AEs.  The parent(s)/legal guardian(s) will be provided with an e-diary  (or e -diary  
application), thermometer ,and measuring device and instructed to collect prompted local 
reactions (redness, s welling ,and pain at the injection site) and s ystemic events (fever, 
decreased appetite, drowsiness/increased sleep ,and irritability ) occurring within 7 day s after 
each vaccination. Use of antipy retic/pain medications will also be prompted for and 
collected dail y in the e -diary  for 7 day s after vaccination.  The participant’s parent(s)/legal 
guardian(s) will be instructed to contact [CONTACT_43038] y staff if the participant experiences redness 
or swelling >14 caliper units, severe pain at the injection sit e,orfever >40.0°C (>104.0°F) in 
the 7 day s after vaccination or has an emergency  room visit or hospi[INVESTIGATOR_059].
Participants will return for Visit 2 (42 to 63 day s after Visit 1, study  Day  43 to 64) and Visit 
3 (42 to 
63days after Visit 2); they  will be assessed for continued eligibility  and information 
will be collected from the participants ’ parent(s)/legal guardian(s) on AEs, including 
nonserious AEs, SAEs, NDCMCs, and e -diary  follow -up (as needed).  Concomitant 
medic ations used to treat SAEs or NDCMCs will be recorded.
Information on vaccines administered since the last visit will also be recorded.  Participants 
with continued eligibility will be administered Dose 2 (Visit 2) and Dose 3 (Visit 3), 
observed for 30 minutes ,and given the same instructions as in Visit 1.
Participants will return for Visit 4 , approximately  1 month (28 to 42 day s)after Visit 3.  
Information will be collected from the participants’ parent(s)/legal guardian(s) on AEs, 
SAEs, NDCMCs ,and e -diary follow -up (as needed).  Concomitant medications used to treat 
SAEs or NDCMCs will be recorded. Information on vaccines administered since the last 
visit will also be recorded.  Blood will be collected for immunogenicity  assessment.
Participants will re turn for Visit 5 (365 to 455days of age) and be assessed for continued 
eligibility .  Information will be collected from the participants’ parent(s)/legal guardian(s) on 
SAEs, NDCMCs, and e- diary  follow -up (as needed).  Concomitant medications used to trea t 
SAEs or NDCMCs will be recorded. Information on vaccines given since the last visit will 
also be recorded.  Blood will be taken for immunogenicity  assessment prior to vaccination.  
Dose 4 (of 20vPnC or 13vPnC) will be administered at this visit.  Specific concomitant 
vaccines containing measles, mumps, rubella, and varicella antigens will be administered at 
this visit. Participants will be observed for 30 minutes after vaccination and any  reactions 
occurring during that time will be recorded as AEs. Parents/legal guardians will be given an 
e-diary  and instructed as in Visit 1.
Participants will return for Visit 6 , approximately  1 month (28 to 42 day s)after Visit 5.  
Information will be collected from the participants’ parent(s)/legal guardian(s) on AEs, 
SAEs, NDCMCs ,and e -diary  follow -up (as needed).  Concomitant medications used to treat 
SAEs or NDCMCs will be recorded. Information on vaccines given since the last visit will 
also be recorded.  Blood will be taken for immunogenicity  assessment.
Participants will have Visit 7, approximately  6 months (168 to 196 day s) after Visit 5. The 
sites will contact [CONTACT_3038]’ parent(s)/legal guardian(s) via telephone to inquire about 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847400] visit.
Amendment 2 applies to a small number of participants, andwith that the following 
modifications are being introduced into the study  design: 1) the window for Visit 5 (time -
based rather than age -based, as all participants are now age -eligible) , 2) collection of Visit 6 
immunogenicit y blood samples will also be time -based ,after which there is an option of 
conducting Visit 6 by  [CONTACT_756], 
and 3)Visit 7 windows will be modified slightly  and/orbe 
time-based (see S ection 1.3, Schedule of Activities; Section 8.10.5, Visit 5 [ D ose 4 Visit, 
365to 455 Day s of Age ];Section 8.10.6, Visit 6 [Dose 4 Follow -up Visit, 28 to 42 Day s 
After Dose 4
];and Section 8.10.7, Visit 7 [ Dose 4 6 -Month Visit, 168 to 196 Day s After 
Dose 4 ]
).  These modified follow - up windows are consistent with the original protocol as
they will still allow for approximately  6 months of follow -up after the final vaccination in the 
series.
4.1.1. Approximate Duration of Participation for Each Participant
Each participant will participate in the study  for approximately  16to 19 months.
4.1.2. Approxima te Number of Participants
Approximately  2000 participants will be enrolled to achieve a target of 1600 evaluable 
participants (800 in each vaccine group) at the follow
-up time point 1 month after Dose 3.
4.2.Scientific Rationale for Study Design
 
 
Infants ≥42 to ≤98 day s of age will be eligible if they  
are naïve to pneumococcal vaccination. This study  population has been selected as this is the 
historical population studied for licensure of 13vPnC in infants. The participants will be 
administered either 20vPnC or 13vPnC at 2, 4, 6, and 12 to 15 months of age. This is 
consistent with the current pneumococcal vaccine recommendations for infants in the United 
States.3113vPnC will serve as the comparator to 20vPnC for assessment of safet y and 
immunogenicit y.
4.3.Justification for Dose
The 20vPnC candidate is modeled after 7vPnC and 13vPnC, and contains capsular 
polysacchari des from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 
14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually  conjugated to CRM 197. The vaccine 
is formulated to contain 2.2 µg of each saccharide, except for 4.4 µg of 6B, per 0.5 -mL dose.
In infants, 
administration of 3 doses of pneumococcal conjugate vaccine given in infancy  at 
2, 4, and 6 months of age, and 1dose given at 12 to 15 months of age ,induces protective 
immune responses.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847401] y:
Age and Sex:
1.Male or female i nfants born at >36 weeks of gestation and 2 months of age 
(≥42 to≤98days) at the time of consent (the day  of birth is considered day  of life 1) .
Type of Participant and Disease Characteristics:
2. Participants whose parent(s)/legal guardian(s) is willing and able to comply  with all 
scheduled visits, treatment plan, and other stud y procedures.
3.Health y infants determined by [CONTACT_13113] ,including medical history and clinical 
judgment ,to be eligible for the study .
4.Expected to be available for the dur ation of the study  and whose parent(s)/legal 
guardian(s) can be contact[INVESTIGATOR_530] b y telephone during study participation.
Informed Consent:
5.Participants whose parent(s)/legal guardian(s) is capable of giving signed informed 
consent as described in Appendix 1 , which includes compliance with the requirements 
and restrictions listed in the informed consent document (I CD) and in this protocol.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847402] y:
Medical Conditions:
1.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg ,anaphy laxis) to any  component of investigational product or any  diphtheria 
toxoid –containing vaccine .
2.
Significant neurological disorder or history  of seizure including febrile seizure or 
significant stable or evolving disorders such as cerebral palsy , encephalopathy , 
hydrocephalus, or other significant disorders. Does not include resolving s yndromes due 
to birth trauma, such as Erb’s palsy and/or h ypotonic -hyporesponsive epi[INVESTIGATOR_1841].
3. Major known congenital malformation or serious chronic disorder.
4.History  of microbiologically  proven invasive disease caused by  [CONTACT_93293] .
5.Known or suspected immunodeficiency  or other conditions associate
d with 
immunosuppression, including, but not limited to, immunoglobulin class/subclass
deficiencies, DiGeorge sy ndrome, generalized malignancy , human immunodeficiency  
virus (HIV) infection, leukemia, ly mphoma ,or organ or bone marrow transplant.
6.Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
7.Congenital, functional, or surgical asplenia.
8.Other acute or chronic medical or ps ychiatric condition or labora tory abnormality  that 
may increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the participant inappro priate for entry  into this 
study .
Prior/Concomitant Therapy:
9. Previous vaccination with any  licensed or investigational pneumococcal vaccine, or 
planned receipt through study  participation.
10.Prior receipt of diphtheria, tetanus, pertussis, poliomy elitis ,and/or 
Hib vaccine.
11. Previous receipt of >1 dose of hepatitis B vaccine; or receipt of a single hepatitis B 
vaccine dose administered at >30 day s old.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847403] blood draw (Visit 6) .  If 
systemic corticosteroids have been administered short term (<14 day s) for treatment of an 
acute illness, participants should not be enrolled into the study  until corticosteroid 
therap y has been discontinued for at least [ADDRESS_847404] 
administration.  I nhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin, eyes, or 
ears) corticosteroids are permitted.
13.Receipt of blood/plasma products or immunogl obulins (including hepatitis B 
immunoglobulin) since birth or planned receipt through the last planned blood draw in 
the study  (through Visit 6).
Prior/Concurrent Clinical Study Experience:
14.Participation in other studies involving investigational drug(s), investigational vaccines, 
or investigational devices within 28 day s prior to study  entry  and/or during study  
participation or intrauterine exposure to investigational vaccines .  Participation in purely  
observational studies is acceptable.
Diagnostic Assess ments:
Not applicable .
Other Exclusions:
15.
Children or grandchildren who are direct descendants of investigator site staff members 
or [COMPANY_007] employees who are dire ctly involved in the conduct of the stud y.
5.3.Lifestyle Considerations
No restrictions are required.
5.4.Screen Failures
Screen failures are defined as participants whose parent(s)/legal guardian(s) have consented 
for them to participate in the clinical study  but are not subsequently  randomly  assigned to 
investigational product/entered in the stud y.  A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  auth
orities.  Minimal information includes demography , 
screen failure details, eligibility  criteria, and any  AEs and SAEs.
Individuals who do not meet the criteria for participation in this study  (screen failures) may  
not be rescreened.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 385.5.Temporary Delay Criteri a
The following conditions are temporary  or self -limiting and a participant may  be vaccinated 
and/or have blood drawn in the study  once the condition(s) has/have resolved and no other 
exclusion criteria are met.
The blood draws prior to vaccination should take place on the same day  as the vaccination.
5.5.1. Criteria for Temporarily Delaying Vaccine Administration
Current febrile illness (eg ,rectal temperature ≥38.0°C [ ≥ 100.4 °F]) or other acute illness 
within [ADDRESS_847405] administration.
Receipt of an y inactivated or otherwise nonlive vaccine within [ADDRESS_847406] administration , with the exception s 
of:
1) influenza vaccine ,which may  be given at any  time during the influenza season if 
the participant is of the appropriate age to receive it ; and 2) permitt ed concomitant 
vaccines on the same day as Dose 1, 2, 3, or 4 (see Section 6.5.2).
Receipt of short -term (<14 day s) systemic corticosteroids. Investigational product 
administration should be delay ed until sy stemic corticosteroid use has been discontinued 
for at least 28 day s.  Inhaled/nebulized, intra-articular, intrabursal
,or topi[INVESTIGATOR_2855] (skin, eyes, 
or ears ) corticosteroids are permitted.
5.5.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw
Receipt of antibiotic therapy  within 72 hours before blood draw. Topi[INVESTIGATOR_634665].
6. STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol , the term investigational product may  be used 
synony mously  with study  intervention.
6.1.Study Intervention(s) Administered
20vPnC is a sterile liquid suspension formulation containing saccharides from pneumococcal 
seroty pes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 
and 33F individually  conjugated to CRM 197.The vaccine is formulated to contain 2.2 µg of 
each saccharide, except for 4.4 µg of 6B, per 0.5 -mL dose. The vaccine contains 5 mM 
succinate buffer, 150 mM sodium chloride, 0.02% poly sorbate 80, and 125 µg aluminum as 
aluminum phosphate, per 0.5
-mL dose.
13vPnC is a sterile liquid suspension formulation containing saccharides from pneumococcal 
seroty pes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individual ly conjugated to 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 39CRM 197. The vaccine is formulated to contain 2.2 µg of each saccharide, except for 4.4 µg 
of 6B, per 0.5-mL dose. The vaccine contains 295 μg succinate buffer, 0.85% sodium 
chloride, [ADDRESS_847407] manual ( IPmanual) and applicable SRSD. 
The vaccine will be supplied as a prefilled sy ringe.
Hibvaccine is a vaccine indicated for the prevention of invasive disease caused by  [CONTACT_634680]. The 
vaccine will be supplied in vials.
MMR is a live virus vaccine for vaccination against measles (rubeola), mumps, and rubella 
(German measles).  See the IP manual and applicable SRSD provided. The vaccine will be 
supplied in vials.
Varicella vaccine i s a live virus vaccine for vaccination against varicella. See the IP manual 
and applicable SRSD. The vaccine will be supplied in vials.
All vaccines listed in this section will be provided by  [CONTACT_634681] s yringes or vials. 
Each s yringe/vial will be packaged in a carton with a label and a tamper -evident seal, and 
will be labeled as required per country  requirement (refer to the IP manual).
6.1.1. Administration
Participants will receive 1 dose of 20vPnC or 13vPnC at each vaccination visit (Visits 1, 2, 3 , 
and 5 with Doses 1, 2, 3, and 4, respectivel y) in accordance with the stud y’s SoA.
They  will also receive 1 dose of a DTaP -containing vaccine in combination with other 
antigens (including polio virus and hepatitis B) and 1 dose of a Hib vaccine at Visits 1, 2 ,and 
3. MMR and varicella vaccine s
will be administered concomitantl y with 20vPnC or 13vPnC 
at Visit 5 with Dose 4 in accordance with the study’s SoA.
20vPnC and 13vPnC should be administered intramuscula rly by [CONTACT_44579] 0.[ADDRESS_847408] be given in a 
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 40limb other than the left leg, as appropriate for the age of the child and the route of 
administration (ie, intramuscular or subcutaneous).
Standard vaccination practices must be observed and vaccine must not be injec ted into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of investigationa l products should be performed by  [CONTACT_634682], Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the 
study  staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as all owed by  [CONTACT_5737], state, and institutional guidance.
Investigational product administration details will be recorded on the case report form (CRF).
6.1.2. Medical Devices
In this stud y, medical devices being deplo yed are the 20vPnC, 13vPnC, and DTaP
combination vacc ine prefilled sy ringes.
Instructions for medical device use are provided in the I P manual or in the package insert.
Medical device deficiencies, including those resulting from malfunctions of the device, must 
be detected, documented, and reported b y the st udy personnel throughout the study .  Please 
refer to Section 8.3.6 for details.
6.2.Preparation/Handling/Storage/Accountability
1.The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  interventions received and any  discrepancies are 
reported and resolved before use of the stud
y intervention, as applicable for 
temper ature -monitored shipments.
 
  
  
 
 
 
 
 
 
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847409] should be prepared and dispensed by  [CONTACT_160440] y qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidance.
6.3.Measures to Minimize Bias: Randomiza tion and Blinding
6.3.1. Allocation to Investigational Product
All eligible participants will be randomized in a 1:1 ratio to receive either 20vPnC or 13vPnC 
(control vaccine).
Allocation of participants to vaccine groups will proceed through the use of an intera ctive 
response technology  (IRT) sy stem (interactive Web -based response [I WR]).  The site 
personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s identification (ID) and pas sword, the 
protocol number, and the participant number.  The site personnel will then be provided with a 
vaccine assignment, randomization number, and dispensable unit (DU) or container number 
when investigational product is being supplied via the I RT s ystem.  The IRT sy stem will 
provide a confirmation report containing the participant number, randomization number, and 
DU or container number assigned.  The confirmation report must be stored in the site’s files .
The study -specific I RT reference manual and I Pmanual will provide the contact [CONTACT_19974] s ystem.
6.3.2. B linding of the Sponsor
Sponsor personnel directly involved in evaluating participant data will be blinded to vaccine 
assignment until the analysis of available data through 1 month after Dose 4,following the 
principles outlined in International Council for Harmonisation ( ICH
) E9 guideline on 
Statistical Principles for Clinical Trials.72A data blinding plan will be created to describe the 
blinding requirements and unblinding events. Laboratory  personnel performing the 
immunologic assay s will be blinded until all assays have bee n completed and assay  results 
finalized.
6.3.3. Breaking the Blind
The study  will be participant -and investigator -blinded.
At the initiation of the study , the investigator site will be instructed on the method for 
breaking the blind for an individual participant.  The method will be an electronic process.  
Blinding codes should be broken onl y in exceptional circumstances when knowledge of the 
actual treatment code is absolutely  essential for further management of the participant.  
Investigators are encouraged to discuss with a member of the study  team if they  believe that 
unblinding is necessary .  When the blinding code is broken, the reason must be recorded in 
the source 
documentation and entered on the CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847410] will be administered by  [CONTACT_110443].
6.5.Concomitant Therapy
6.5.1. Prohibited Concomitant Vaccines and Treatments
Receipt of an y investigational vaccines, drugs, or medical devices is prohibited during 
study  participation.
Receipt of nonstudy  pneumococcal vaccine is prohibited during study  participation.
Receipt of blood/plasma products, immunoglobulins, and/or immunosuppressive therap y 
(including a ≥14- day course of s ystemic corticosteroids) is prohib ited through Visit 6.
6.5.2. Permitted Concomitant Vaccines and Treatments
Influenza vaccine is permitted at any  time during influenza season in this study , if the 
participant is eligible to receive in fluenza vaccine.
Rotavirus vaccine may  be given at an y time during the study , and according to local or 
national recommendations.
Receipt of quadrivalent meningococcal conjugate vaccine is permit ted during the stud y 
only after blood is collected at the visit occurring 1 month after Dose 4.
Other nonprohibited lice nsed vaccines may  be given between the blood draw 1 month 
after Dose 3 (Visit 4) and 14 day s before Dose 4 (Visit 5) for inactivated vaccines or 
28days before Dose 4 (Visit 5) for live vaccines, according to local or national 
recommendations.  Following the blood draw performed 1 month after Dose 4 (Visit 6), 
all licensed vaccines are permitted.
Use of topi[INVESTIGATOR_634666].
The use of proph ylactic antipy retic/pain medication, while permitted, is not 
recommended on the day prior to vaccination or the day  of investigational product 
administration.
Inhaled/nebulized, topi[INVESTIGATOR_2855] (skin, ey es, or ears), or localized injections of corticosteroids 
(eg, intra -articular or intrabursal administration) are permitted during participant 
participation in the study .
Prescription and nonprescription medications, vitamins, minerals ,and herbal remedies 
are permitted during the study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 446.5.3. Recording Prior and Concomitant Vaccines and Treatments
The name [CONTACT_634694] m the time of 
signing of the ICD to Visit 6 and will be recorded in the CRF.  At Visit 1, information on 
prior vaccinations will also be recorded in the CRF. Vaccines required b y the protocol, as 
well as those not stipulated, will be recorded throughout s tudy participation.  I nformation on 
vaccines given to the participant’s mother during pregnancy  and any  intrapartum antibiotic 
use will also be collected (at Visit 1 only ), if available.
Medications taken to treat SAEs or NDCMCs from the signing of informe d consent to the 
final visit will be recorded in the CRF.
6.6. Dose Modification
Not applicable .
6.7.Intervention After the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PA RTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Participant eligibility  must be confirmed prior to each vaccination in order to continue in the 
study .
If a participant no longer meets the eligibility  criteria during the vaccination period of the 
study , further vaccinations should be discontinued, but the participant may  remain in the 
study .  If a participant is discontinued from vaccination and the parti cipant’s parent(s)/legal 
guardian(s) consents, safety  follow -up will be conducted as per Section 8.3 (AEs will be 
collected for [ADDRESS_847411] study  vaccination).
See the 
SoA for data to be collected at the time of intervention discontinuation and follow -up 
and for an y further evaluati ons that need to be completed.
7.2.Participant Discontinuation/Withdrawal From the Study
A participant may be withdrawn from the study  at any  time at the request of his/her 
parent(s)/legal guardian(s) or may  be withdrawn at any  time at the discretion of the 
investigator for safety, behavioral, compliance, or administrative reasons.
If a participant does not return for a scheduled visit, every  effort should be made to contact 
[CONTACT_2299]’s parent(s)/legal guardian(s). All attempts to contact [CONTACT_2299] ’s 
parent(s)/legal guardian(s) and information received during contact [CONTACT_407399]’s source document. In any circumstance, every  effort should 
be made to document participant outcome, if possible.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 45At the time of discontinuing please refer to the investigator site file (ISF)and SoA for 
assessments to be collected at the time of stud y discontinuation and follow -up and for an y 
further evaluations that need to be completed.
The participant’s p arent(s)/legal guardian(s) should ideally  notify  the investigator in writing 
of the decision to withdraw consent from future follow- up, whenever possible. The 
participant’s parent(s)/legal guardian(s) should be questioned regarding their reason for 
withdr awal. The investigator or his or her designee should capture the reason for withdrawal 
in the CRF for all participants.
The participant should be requested to return for a final visit, if applicable, and the 
investigator will perform the procedures indica ted for the next visit. Any AEs or SAEs that 
are continuing at the time of withdrawal from the study should be followed until resolution 
or, in case of permanent impairment, until the condition stabilizes.
For p articipants who are discontinued prior to completing all 4 doses of study  intervention , 
the parents/guardians should be encouraged to follow up with their primary care ph ysician to 
have the participant complete the pneumococcal conjugate vaccine series with commercial
Prevnar [ADDRESS_847412] vaccination (similar to that described in 
Section 8.10.7) for the collection of safet y information should be completed for all 
participants who have been withdraw n
after administration of investigational product, unless 
consent for further contact [CONTACT_346263], or the participant is lost to follow -up.
Participant withdrawal should be explained in the source documents and should include 
whether the withdrawal is only  from further receipt of investigational product or also from 
study  procedur es and/or posttreatment study  follow -up.
If a participant is withdrawn from the stud y, his/her parent(s)/legal guardian(s) may request 
destruction of an y remaining samples, but data alread y generated from the samples will 
continue to be available, and may  be used to protect the integrity  of existing anal yses.  The 
investigator must document an y such requests in the site study records.
If the participant is withdrawn from the study  and his/her parent(s)/legal guardian(s) also 
withdraws consent (see below) fo
r disclosure of future information, no further evaluations 
should be performed and no additional data should be collected.  The sponsor may  retain and 
continue to use an y data collected before such withdrawal of consent.
When a participant is withdrawn fro m the study  because of an SAE, the SAE must be 
recorded on the CRF and reported on the Vaccine SAE Report ing Form.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847413] to follow- up if he or she repeatedl y fails to return for 
scheduled visits and the participant’s parent(s)/legal guardian(s) is unable to be contact[INVESTIGATOR_530] b y 
the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit or fails to respond to the 6- month safety  follow -up telephone call:
The site must attempt to contact [CONTACT_2299]’s parent(s)/legal guardian(s ) and 
reschedule the missed visit as soon as possible and counsel the participant’s 
parent(s)/legal guardian(s) on the importance of maintaining the assigned visit schedule 
and ascertain whether or not the participant’s parent(s)/legal guardian(s) wishes t he 
participant to, and/or should, continue in the study;
Before a participant is deemed lost to follow
-up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635]’s parent(s)/legal guardian(s) (where 
possible, 3 telephone calls and, if necessary , a certified letter to the participant’s last 
known mailing address or local equivalent methods).  These contact [CONTACT_19425]’s medical record;
Should the participant’s parent(s)/legal guardian(s ) continue to be unreachable, the 
participant will be considered to have been withdrawn from the study .
Discontinuation of specific sites or of the study  as a whole is handled as part of Appendix 1 .
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA.  Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the stud y design re quirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The invest igator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847414] information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this study  is approximately  
15mL.
8.1.Efficacy Assessments
8.1.1. Immunogenicity Assessments
Blood samples (approximately  5mL per sample) will be collected from all participants at 
Visit 4 (1 month after Dose 3), Visit 5 (prior to administration of Dose 4), and Visit 6 
(1month after Dose 4).  These are the immunogenicity  time points.
Pneumococcal Responses
IgG Responses to the 20 Seroty pes Contained in 20vPnC
IgG antibod y concentrations for serot ypes present in 20vPnC (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 
10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) will be determined on all sera 
collected at the 3 immunogenicity  time poi nts (Visits 4, 5, and 6).  The seroty pe-specific IgG 
concentrations will be measured b y [COMPANY_007]’s multiplex L uminex immunoassay .
OPA Responses to the 20 Seroty pes Contained in 20vPnC
OPA titers for serot ypes present in 20vPnC (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 
15B, 18C, 19A, 19F, 22F, 23F, and 33F) will be determined in randoml y selected subsets of 
sera for the immunogenicity  time points (Visits 4, 5, and 6). Thesesubsets will 
be randomly  
selected, b y an unblinded third party, to assure tha t each subset has equal representation of 
both vaccine groups. Further details will be described in the clinical specimen assessment 
plan (CSAP) .
 
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 48Concomitant Vaccine Antigens
Responses to the following concomitant vaccine antigens will be assessed.  The randoml y 
selected ser umsubsets to be assay ed will be based on minimum sample sizes needed to 
demonstrate the objectives of the stud y balanced with the ser umvolume required and 
available for testing.
Diphtheria toxoid: Concentration of antibody  (in international units [ IU]) to diphtheria toxoid 
(predefined level ≥0.1 IU/mL ) will be determined on subsets of sera collected at the 
immunogenicit y time point 1 month after Dose 3.  
Tetanus toxoid: Conce ntration of antibody  (in IU)to tetanus toxoid (predefined level 
≥0.1 IU/mL) will be determined on subsets of sera collected at the immunogenicity  time 
point 1 month after Dose 3.   
Acellular pertussis: Concentration of IgG antibodies to pertussis antigens PT , FHA , and PRN
(predefined level ≥ the observed antipertussis antibody  concentration achieved by  95% of 
13vPnC recipi[INVESTIGATOR_840]) will be determined on subsets of sera collected at the imm unogenicit y 
time point 1 month after Dose 3.  
Hepatitis B: Concentration of hepatitis B antibody  (in milli
-international units per mL  
[mIU/mL ]) (predefined level ≥10 mIU/mL) will be determined on subsets of sera collected at 
the immunogenicit y time point 1 month after Dose 3 (Visit 4).  
Poliomy elitis: Neutralizing antibody  (NA) titers to poliovirus ty pes 1, 2, and 3 (predefined 
level NA titer ≥1:8) will be determined on subsets of sera collected at the immunogenicit y 
time point 1 month after Dose 3.  
Hib: Concentration of anti body  to Hib (poly ribosylribitol phosphate [ PRP])in µg/mL  
(primary  predefined level ≥0.15 µg/mL  anti-PR P; alternative predefined level ≥1.0 µg/mL  
anti-PRP) will be determined on subsets of sera collected at the immunogenicity  time point 
1month after Dose 3.  
Measles :Concentration of antimeasles antibod y will be determined on subsets of sera 
collected at 1 immunogenicity  time point (1 month after Dose 4 [ Visit 6 ]).  
Mumps :Concentration of antimumps antibody  will be determined on subsets of sera 
collected at 1 immunogenicity  time point (1 month after Dose 4 [ Visit 6 ]).  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 49Rubella :Concentration of antirubella antibod y will be determined on subsets of sera 
collected at 1 immunogenicity  time point (1 month after Dose 4 [Visit 6 ]).  
Varicella :Concentration of 
antivaricella antibody  will be determined on subsets of sera 
collected at 1 immunogenicity  time point (1 month after Dose 4 [ Visit 6 ]).  
 
8.1.2. Biological Samples
Blood 
samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory  personnel testing the samples will not know the participant’s 
identity .  Samples that remain after performing assay s outlined in the protocol may  be stored 
by [CONTACT_4618].  Unless a time limitation is required by  [CONTACT_240846], 
the samples will be stored for up to 15 y ears after the end of the study  and then destro yed.   
 
 No testing of the participant’s genetic material will be performed.
The participant’s parent(s)/legal guardian(s) may  request that the participant’s samples, if 
still identifiable, be destroy ed at any  time; however, an y data alrea dy collected from those 
samples will still be used for this research.  The biological samples may  be shared with other 
researchers as long as confidentiality  is maintained and no testing of the participant’s genetic 
material is performed.
8.2.Safety Assessments
A clinical assessment, including medical history  and measurement of rectal temperature ,will 
be performed on all participants prior to vaccination to determine participant eligibility  and 
to establish a clinical baseline.  Significant medical h istory  and significant findings from an y 
physical examination (if performed) will be recorded as medical history  in the CRF.  
Temperature measurement prior to vaccination will be documented and recorded in the CRF.
The participant will be observed for 30 m inutes after each study  vaccination and any  
reactions occurring during that time will be recorded as AEs.
Prompted e -diary  events, including local reactions (redness, swelling , and pain at the
injection site) and systemic events (fever, decreased appetite, drowsiness/increased sleep, and 
irritability ) that occur [ADDRESS_847415] administration (Day s 1 through 7, 
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 50where Day  1 is the day  of vaccination), are graded as described in Section 8.2.2.  
Furthermore, AEs, SAEs, and NDCMCs will be collected as defined in Section 10.3.
Planned time points for all safety  assessments are provided in the 
SoA.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
8.2.1. Participant E lectronic Diary
The participant’s parent(s)/legal guardian(s) will be asked to monitor and record local 
reactions, specific s ystemic events, and antipy retic/pain medication taken for 7 day s, each 
evening ,following each study  vaccination using an e -diary  (in a provisioned device or 
application on a personal device). This allows recording of these assessments only  within a 
fixed time window, thus providing the accurate representation of the participant’s experience.  
Data on local reactions, specific s ystemic events, and antipy retic/pain medication reported in 
the e -diary  will be transferred electronicall y to the e -diary  vendor, where they  will be 
available for review b y investigators, their qualified designees, and sponsor staff at all times 
via an internet -based portal.  At intervals agreed to by  [CONTACT_407401], these data will 
be transferred electronically  to [COMPANY_007] for analy sis and reporting.
The daily  e-diary  data will not be captured in the CRF .  However, if a participant is 
withdrawn because of prompted events reported in the e
-diary , the event(s) should be 
recorded on the AE page of the CRF, regardless of whether the investigator considers the 
event(s) to be clinically  significant.
The investi gator or designee must obtain stop dates for an y local reactions orspecific 
systemic events on the last day  that the e -diary  was completed.  The stop dates should be 
entered in the CRF.
Investigators (or an appropriately  qualified designee) are required t o review the e -diary  data 
online at frequent intervals (daily  is optimal) to evaluate participant compliance and reported 
events as part of the ongoing safet y review.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 518.2.2. Grading Scale for Prompted Events
The grading scales used in this study  to assess prompte d events as described below are based 
on concepts outlined in the FDA Center for Biologics Evaluation and Research (CBER) 
guidelines on toxicity  grading scales for adults and adolescent volunteers enrolled in 
preventive vaccine clinical trials, but have be en adapted for applicability  to healthy  infants.73
[IP_ADDRESS]. Local Reactions
For the first 7 day s following each stud y vaccination (Day s 1 through 7, where Day  1 is the 
day of vaccination), the participant’s parent(s)/legal guardian(s) will be asked to assess 
redness , swelling, and pain at the 20vPnC or 13vPn Cinjection site and to record the 
symptoms in the e -diary  in the evening.  Redness and swelling will be measured and 
recorded in measuring device (caliper) units (range: 1 to >14; an entry  in the e -diary  of 
15will denote >14), and then categorized during analy sis as mild, moderate, or severe based 
on the grading scale in Table 1.  Measuring device units can be converted to cen timeters 
according to the following scale: 1
measuring device unit = 0.5 cm.  Pain at the vaccine 
injection site will be assessed by  [CONTACT_2299]’s parent(s)/legal guardian(s) as mild, 
moderate, or severe according to the grading scale in Table 1.  The participant’s 
parent(s)/legal guardian(s) will be prompted to contact [CONTACT_634683] a severe (Grade 3 or above) local reaction to asse ss the reaction and perform an 
unscheduled assessment or visit as appropriate.
Only  an investigator is able to classify
 a participant’s local reaction as Grade 4, after ph ysical 
examination of the participant or documentation from another medicall y qualified source 
(eg, emergency  room or hospi[INVESTIGATOR_8735]).  If a participant experiences a Grade [ADDRESS_847416] immediately  notify  the sponsor. Site staff will educate the 
participant’s parent(s)/legal guardian(s) regarding signs and s ymptoms that would prompt 
site contact.
The procedure for notification of the sponsor is provided in the ISFor equivalent.
Table 1. Grading Scales for Local Reactions
Local Reaction GRADE 1
mildGRADE 2 
moderateGRADE 3a
severeGRADE 4b
Redness 1 to 4 caliper units
(or measuring device 
units)
=
>0 to 2.0 cm5 to 14 caliper 
units
(or measuring 
device units)
=
>2.0 to 7.0 cm>14 caliper 
units (or 
measuring 
device units)
=
>7 cmNecrosis or exfoliative 
dermatitis

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 52Table 1. Grading Scales for Local Reactions
Local Reaction GRADE 1
mildGRADE 2 
moderateGRADE 3a
severeGRADE 4b
Swelling 1 to 4 caliper units
(or measuring device 
units)
=
>0 to 2.0 cm5 to 14 caliper 
units
(or measuring 
device units)
=
>2.0 to 7.0 cm>14 caliper 
units (or 
measuring 
device units)
=
>7 cmNecrosis
Pain at injection site 
(tenderness)Hurts if gently 
touched
(eg,whimpers, 
winces, protests ,or 
withdraws)Hurts if gently 
touched with 
cryingCauses 
limitation of 
limb movementEmergency room visit or 
hospi[INVESTIGATOR_634667] (tenderness) at 
injection site
Abbreviations: CRF = case report form; e -diary = electronic diary.
a.Parents/legal guardians of the participants experiencing local reactions >14 caliper units (>7.0 cm) are to 
be contact[CONTACT_9298]. An unscheduled visit may be required.
b.Grade 4 assessment should be made by [CONTACT_093]. Grade 4 w ill not be collected in the e -diary but 
will be collected as an AE on the CRF. The s everity of the local reaction should be graded using the AE 
grading scale in Section 10.3.4 .
Note : If the size of the redness and/or swelling falls between 2 measuring device units, the higher measuring 
device unit number will be recorded in the e -diary.
[IP_ADDRESS]. Systemic Events (Systemic Symptoms and Fever)
For the first 7 day s following each stud y vaccination (Day s 1 through 7, where Day  1 is the 
day of vaccination), the participant’s parent(s)/legal guardian(s) will be asked to assess 
decreased appetite, drowsiness/increased sleep, and irritability  and to record the sy mptoms in 
the e -diary  (in a provisioned device or application on a person al device) in the evening.  The 
symptoms will be assessed by  [CONTACT_2299]’s parent(s)/legal guardian(s) as mild, moderate, 
or severe according to the grading scale in Table 2.  The participant’s parent(s)/legal 
guardian(s) will also be instructed to contact [CONTACT_634684] y 
possible Grade 4 prompted sy stemic event (ie, emergency  room vi sit or hospi[INVESTIGATOR_634668], severe drowsiness/increased sleep, or severe irritability ) within 
7days after vaccination.  Study  staff may  also contact [CONTACT_2299]’s parent(s)/legal 
guardian(s) to obtain additional information o n Grade 3 events entered into the e -diary .
Only  an investigator is able to classify  a participant’s sy stemic event as Grade 4, after 
physical examination of the participant or documentation from another medically  qualified 
source (eg, emergency  room or hos
pi[INVESTIGATOR_8735]) or telephone contact [CONTACT_6635]’s 
parent(s)/legal guardian(s).  If a participant experiences a Grade [ADDRESS_847417] immediately  notify  the sponsor.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 53The procedure for notification of the sponsor is provided i n the ISF or equivalent.
Table 2. Grading Scales for Systemic Event Symptoms
Systemic Event GRADE 1
mildGRADE 2 
moderateGRADE 3
SevereGRADE 4a
Decreased appetite 
(loss of appetite)Decreased interest in 
eatingDecreased oral 
intakeRefusal to feed Emergency room visit 
or hospi[INVESTIGATOR_383784] (loss of 
appetite)
Drow siness
(increased sleep )Increased or 
prolonged sleepi[INVESTIGATOR_634669] 
(increased sleep)
Irritability
(fussiness)
(synonym ouswith 
restless sleep; 
decreased sleep)Easily consolable Requiring 
increased 
attentionInconsolable; 
crying cannot 
be comfortedEmergency room visit 
or hospi[INVESTIGATOR_383787] 
(fussiness)
Abbreviations: CRF = case report form; e -diary = electronic diary.
a.Grade 4 assessment should be made by [CONTACT_093]. Grade 4 w ill not be collected in the e -diary but
will be collected as an AE on the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale in Section 10.3.4 .
[IP_ADDRESS].1. Fever
In order to record information on fever, a digital thermometer will be given to the 
participant’s parent(s)/legal guardian(s) with instructions on how to measure rectal 
temperature at home.  Temperature will be collected in the evening, daily,for 7 day s 
following each stud y vaccination (Day s 1 through 7, where Day  1 is the day of vaccination) 
and at an y time during the 7 day s that fever is suspected.  Fever is defined as a rectal 
temperature of ≥38.0°C ( ≥ 100.4 °F).  The highest tempera ture for each day  will be recorded 
in the e
-diary .  In the event of a fever on Day  7, temperature will be collected daily  until 
fever has resolved (1 day of temperature less than 38.0°C [100.4 °F]) in order to collect a stop 
date in the CRF.  A participant’s parent(s)/legal guardian(s) will be prompted to contact [CONTACT_407404] a fever >40.0
°C (>104.0°F) within the 7 day s 
following vaccination to assess the fever and perform an unscheduled assessment, as 
applicabl e (see Section 8.10.8 ).  Study  staff may  also contact [CONTACT_2299]’s parent(s)/legal 
guardian(s) to obtain additional information if a temperature of >38.9 °C (>102.0 °F) is 
entered into an e -diary .  Temperature will be measured and recorded to [ADDRESS_847418] and 
then grouped into ranges for the analy sis; see Table 3.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 54Table 3. Ranges for Fever
≥38.0 °C to 38.4 °
C
>38.4 °C to 38.9 °C
>38.9 °C to 40.0 °C
>40.0 °C
Note : Fever is defined as temperature ≥38.0°C.
[IP_ADDRESS]. Use of Antipyretic/Pain Medication
The participant’s parent(s)/legal guardian(s) will be asked to record the use of 
antipy retic/pain medication (y es/no) in the e -diary (in a provisioned device or application on 
a personal device) in the evening
,daily,for [ADDRESS_847419].
8.2.3. Clinical Safety L aboratory Assessments
Clinical safety  laboratory tests are not required by  [CONTACT_3181].
If laboratory  values from non–protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
8.3.Adverse Events and Seri ous Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant’s parent(s)/legal guardian(s). Events that, in the 
clinical judgment of the investigator, are 1) consistent with normal growth and development 
and 2) do not differ significantly  in frequency  or severit y from expected are not generally to 
be considered AE s. Examples may  include, but are not limited to, teething, contact [CONTACT_407405], spi[INVESTIGATOR_322054], colic, or ty pi[INVESTIGATOR_407372]/cry ing in infants and children.
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or caused the participant to discontinue from
the study  (see Section 7).
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant’s parent(s)/legal guardian(s) 
provides informed consent, which is obtained before the participant’s participation in the 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 55study  (ie, before undergoing an y stud y-related procedure and/or receiving investigational 
product), through and including Visit 4 and from Visit 5 t hrough Visit 6.  Between Visit 4 
and Visit 5, only  SAEs and NDCMCs will be reported.  At Visit 7 (final telephone contact), 
the participant’s parent(s)/legal guardian(s) will be contact[INVESTIGATOR_530] b y telephone to inquire about 
SAEs, including hospi[INVESTIGATOR_407373], since Visit 6.
Follow -up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
Investigators ar e not obligated to activel y seek AEs or SAEs after conclusion of the study
 
participation.  However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has completed or withdrawn early  from the study , and he/she consid ers the 
event to be reasonabl y related to the study  intervention or study  participation, the investigator 
must promptly  notify  the sponsor.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety  on the Vaccine SAE Reporting Form immediatel y upon awareness and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3.  The investigator will 
submit any  updated SAE data to the sponsor within 24 hours of it being available .
SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at leas t a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS].
Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant’s parent(s)/legal guardian(s) is the preferred 
method to inquire about AE occurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the inve stigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section 7.3).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847420] be submitted as soon as possible to [COMPANY_007] Safety .
Further information on follow -up procedures is given in Appendix 3 (Section 10.3).
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_19990] y of participants and the safet y of a 
study  intervention under clinical investigatio n are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRBs)/ethics committees 
(ECs) , and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) ac cording to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the IBand will notify  the I RB/EC, if appropriate according to local 
requirements.
8.3.5.
Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in females (via occupational exposure) will be collected after the
start of study  intervention and until delivery .
 
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding (via occupational exposure) must be reported, 
irrespective of the presence of an associated SAE, to [COMPANY_007] Safety  within 24 hours of the 
investigator’s awareness, using the Vaccine SAE Reporting Form.  An exposure during 
breastfeeding report is not created when a [COMPANY_007] drug specifically  approved for use in 
breastfeeding women (eg, vitamins) is administered in accord with authorized use.  However, 
if the infant experiences an SAE associated with such a drug’s administration, the SAE is 
reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets i
n unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the Vaccine SAE Reporting Form , regardless of whether there is an 
associated SAE.  Since the information does not pertain to a participant enrolled in the study , 
the information is not recorded on a CRF; however, a cop y of the completed Vaccine SAE 
Reporting Form is maintained in the ISF.
8.3.6. Medical Device Deficiencies
Medical devices are being provided for use in this study  for the purposes of administering the 
investigational product
.  In order to fulfill regulatory  reporting obligations worldwide, the 
investigator is responsible for the detection and documentation of events meeting the 
definitions of deficienc iesthat occur during the study  with such devices.
The definition of a medical device deficiency can be found in Appendix 8 .
NOTE: Deficiencies fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 8.3.3 and Appendix 3 (Section 10.3) of the protocol.
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies or malfunctions of the device will be detected, documented, and 
reported during all periods of the study
 in which the medical device is used.
If the investigator learns of an y device deficiency at an y time after a participant ha s been 
discharged from the study, and such incident is considered reasonabl y related to a medical 
device provided for the study , the investigator will promptly  notify  the sponsor.
The method of documenting medical device deficiencies is provided in Appendix 8
(Section 10.8).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Follow -up of Medical Device Deficiencies
All medical device deficiencies involving an AE will be followed and reported in the same 
manner as other AEs (see Section 8.3.3).  This applies to a ll participants, including those who 
discontinue study  intervention.
The investigator is responsible for ensuring that follow- up includes an y supplemental 
investigations as indicated to elucidate the nature and/or causality  of the 
deficiency .
New or update d information will be recorded on a follow - up form with all changes signed 
and dated b y the investigator.
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor
Device deficiencies will be reported to the sponsor within [ADDRESS_847421] be reported to [COMPANY_007] Safet y 
within 24 hours upon the investigator’s awareness as outlined in Section [IP_ADDRESS] and 
Section [IP_ADDRESS].
The sponsor will be the contact [CONTACT_227989].
Information will be provided to the sponsor as described in the IP manual.
[IP_ADDRESS]. Regulatory Reporting Requirements for Medical Device Deficiencies
The i nvestigator will promptly  report all device deficiencies occurring with any  medical 
device provided for use in the study
 in order for the sponsor to fulfill the legal responsibility  
to notify  appropriate regulatory  authorities and other entities about cert ain safet y information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requireme nts relating to 
the reporting of device deficiencies to the IRB/EC.
8.3.7. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE Reporting Form
to [COMPANY_007] Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 59Medication errors include:
Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
appli cable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within 24 hours on a Vaccine SAE 
Reporting Form only when associated with an SAE.
Other examples include, but are not limited to:
The administration of expi[INVESTIGATOR_149325];
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperature excursion 
from the specified storage range, unless it is determined by [CONTACT_346268].
8.4.Treatment of Overdose
For this study , any  dose of investigational product greater than [ADDRESS_847422] within a 24 -hour time period will be considered an overdose.
[COMPANY_007] does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_10990] .
2.Closely  monitor the participant for an y AEs/SAEs.
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 604.Overdose is reportable to Safety  only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be m ade by
 [CONTACT_78256].
8.5.Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7.Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
8.10. Study Procedures
The study  procedures are summarized in the SoA (Section 1.3). The day  of Dose [ADDRESS_847423] some flexibility .
8.10.1. Visit 1 (Dose 1 Visit, Day 1)
Prior to vaccination:
Obtain a personally  signed and dated ICD indicating that the participant’s parent(s)/legal 
guardian(s) has been informed of all pertinent aspects of the study  before performing any  
study -specific procedures.
Assign a participant number via the IRT.
Obtain and record the participant’s demographic information (including date of birth, sex, 
race,and ethnicit y). The complete date of birth (ie, DD -MMM -
YYYY) will be collected 
to critically  evaluate the immune response and safety  profile by  [CONTACT_654].
Perform a clinical assessment including medical history  (including significant birth 
history ); record any  findings on the medical history  CRF.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 61Record vaccine history .
Record vaccine sreceived during pregnancy  and intrapartum antibiotics (if available).
Measure and record the participant’s rectal temperature ( °C/°F).
Ensure that all inclusion criteria, none of the exclusion criteria ,and none of the temporary  
delay  criteria are met.
Assign a randomization number and an investigational product container number via the 
IRT.  This must be the last step before procee ding.  A site staff member will prepare the 
investigational product according to the IP manual.
After randomization:
Administer a single 0.5 -mL injection of 20vPnC or 13vPnC into the left anterolateral 
thigh.
Administer concomitant vaccines containing diphtheria, tetanus, acellular pertussis, 
hepatitis B, polio virus , and Hib
antigens and other permitted vaccines into a limb other 
than the site of 20vPnC or 13vPnC injection , as appropriate for the age of the child and 
the route of vaccine administration (ie, intramuscular, subcutaneous, or oral) ,and record 
the site of administration on the CRF.
Site staff will observe the participant for [ADDRESS_847424] conco mitant 
medications used to treat SAEs and NDCMCs.
Issue the participant’s parent(s)/legal guardian(s) a measuring device to measure 20vPnC 
or 13vPnC injection site reactions and a digital thermometer and provide instructions on 
their use.
Issue the partici pant’s parent(s)/legal guardian(s) an e -diary  (device or application).  
Provide instructions on use and completion of the e- diary .  Ask the participant’s 
parent(s)/legal guardian(s) to complete the e- diary from Day 1 to Day  7, with Day 1 
being the day  of vaccination.
Ask the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407408] 7 -day postvaccination period if the participant 
has a fever >40.0 °C (>104.0 °F), redness and/or swelling at t he 20vPnC or 13vPnC 
injection site measuring >14 measuring device units (>7 cm), or severe 20vPnC or 
13vPnC injection site pain (causes limitation of limb movement) to determine if the event 
requires further assessment by  [CONTACT_093].

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 62Ask the particip ant’s parent(s)/legal guardian(s) to contact [CONTACT_407409] y significant illness or medical event (eg, emergency  
room visit or hospi[INVESTIGATOR_059]) occurs.
Provide the parent(s)/legal guardian(s) with the participant contact [CONTACT_634685] (see Section 10.1.10 ) .
Inform the participant’s parent(s)/legal guardian(s) that the use of proph ylactic 
antipy retic/pain medication, while permitted, is not recommended on the day  of 
investigational product administration (before or after vaccination).
The investigator or an authorized designee completes the CRF and the source documents 
and updates the investigational product accountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
freque nt intervals for the 7 day s following vaccination to evaluate participant compliance 
and as part of the ongoing safet y review.
8.10.2. Visit 2 (Dose 2 Visit, 42 to 63 Days After Dose 1, ie , Study Day 43 Through Study 
Day 64)
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and none of the temporary  
delay  criteria are met (Section 5.5).
Record nonstud y vaccinations administered since Visit 1, as described in Section 6.5.
Review the participant’s e -diary  data with the participant’s parent(s)/legal guardian(s); 
collect stop dates of an y e
-diary  events ongoing on the last day  that the e -diary  was 
completed an d record stop dates in the CRF.
Determine whether an y AEs (includes nonserious AEs, SAEs, and NDCMCs) have 
occurred since the previous visit and follow up on any  previousl y reported events to 
determine the outcome (ie, record stop dates or confirm if they  are still continuing) and 
record as described in Section 10.3, and record concomitant medications used to treat 
NDCMCs and SAEs.
Measure and record the participant’s rectal temperature ( °C/°F).
Administer a single 0.5 -mL injection of 20vPnC or 13vPnC into the left anterolateral 
thigh.
Administer concomitant vaccines containing diphtheria, tetanus, acellular pertussi s
, 
hepatitis B, polio virus , and Hib antigens and other permitted vaccines into a limb other 
than the site of 20vPnC or 13vPnC injection , as appropriate for the age of the child and 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 63the route of vaccine administration (ie, intramuscular, subcutaneous, or or al),and record 
the site of administration on the CRF.
After vaccination:
Site staff will observe the participant for [ADDRESS_847425] concomitant 
medicatio ns used to treat SAEs and NDCMCs.
Confirm that the e- diary  is working and review instructions if necessary .  Remind the 
participant’s parent(s)/legal guardian(s) to complete the e -diary  from Day 1 to Day  7, 
with Day 1 being the day of vaccination.  Provide athermometer or measuring device if 
needed.
Ask the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407408] 7 -day postvaccination period if the participant 
has a fever >40.0 °C (>104. 0°F), redness and/or swelling at the 20vPnC or 13vPnC 
injection site measuring >14 measuring device units (>7 cm), or severe 20vPnC or 
13vPnC injection site pain (causes limitation of limb movement), to determine if the 
event requires further assessment by [CONTACT_093].
Remind the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407411] y significant illness or medical event 
(eg,emergency  room visit or hospi[INVESTIGATOR_059]) occurs during the study  period.
Confirm whether the parent(s)/legal guardian(s) s till possesses the participant contact 
[CONTACT_1137]. Provide a participant contact [CONTACT_634686].
Remind the participant’s parent(s)/legal guardian(s) that the use of proph ylactic 
antipy retic/pain medication, while permitted, is not recommended on the day  of 
investigational product administration (before or after vaccination).
The investigator or an authorized designees completes the CRF and the source documents 
and updates the investigational product accountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
freque nt intervals for the 7 day s following vaccination to evaluate participant compliance 
and as part of the ongoing safet y review.
8.10.3.
Visit 3 (Dose 3 Visit, 42 to 63 Days After Dose 2)
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and none of the temporary  
delay  criteria are met (Section 5.5).
Record nonstud y vaccinations administered since Visit 2, as described in Section 6.5 .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 64Review the participant’s e -diary  data with the participant’s parent(s)/legal guardian(s); 
collect stop dates of an y e-diary  events ongoing on the last day  that the e -diary  was 
completed and record stop dates in the CRF.
Determine whether an y AEs (includes nonser ious AEs, SAEs, and NDCMCs) have 
occurred since the previous visit and follow up on any  previousl y reported events to 
determine the outcome (ie, record stop dates or confirm if they  are still continuing) and 
record as described in Section 10.3, and record concomitant medications used to treat 
NDCMCs and SAEs.
Measure and record the participant’s rectal temperature ( °C/°F).
Administer a single 0.5 -mL injection of 20vPnC or 13vPnC into the left anterolateral 
thigh.
Administer concomitant vaccines containing diphtheria, tetanus, acellular pertussis , 
hepatitis B, polio virus , and Hib antigens and other permitted vaccines into a limb other 
than the site of 20vPnC or 13vPnC injection, as appropriate for the age of the child and 
the route of vaccine administration (ie
,intramuscular, subcutaneous, or oral) ,andrecord
the site of administration on the CRF.
After vaccination:
Site staff will observe the participant for [ADDRESS_847426] concomitant 
medications used to treat SAEs and NDCMCs.
Confirm that the e- diary  is working and review instructions if necessary .  Remind the 
participant’s parent(s)/legal guardian(s) to complete the e -diary  from Day 1 to Day  7, 
with Day 1 being the day of vaccination.  Provide a thermometer or measuring device if 
needed.
Ask the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407408] 7 -day postvaccination period if the participant 
has a fever >40.0 °C (>104.0 °F), redness and/or swelling at the 20vPnC or 13vPnC 
injection site measuring >14 measuring device units (>7 cm), or severe 20vPnC or 
13vPnC injection site pain (causes limitation of limb movement), to determine if the 
event requires further assessment by  [CONTACT_093].
Remind the participant’s parent(s)/legal guardian (s) to contact [CONTACT_407411] y significant illness or medical event 
(eg,emergency  room visit or hospi[INVESTIGATOR_059]) occurs during the study  period.
Confirm whether the parent(s)/legal guardian(s) still p ossesses the participant contact 
[CONTACT_1137]. Provide a participant contact [CONTACT_634686].

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 65Remind the participant’s parent(s)/legal guardian(s) that the use of proph ylactic 
antipy retic/pain medication, while permitted, is not recommended on the day  of 
investiga tional product administration (before or after vaccination).
The investigator or an authorized designee completes the CRF and the source documents 
and updates the investigational product accountability  records.
8.10.4. Visit 4 ( Dose 3 Follow -up Visit, 28 to 42 Day s After Dose 3)
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and none of the temporary  
delay  criteria are met (Section 5.5).
Record nonstud y vaccinati ons administered since Visit 3, as described in Section 6.5.
Review the participant’s e -diary  data with the participant’s parent(s)/l egal guardian(s); 
collect stop dates of an y e
-diary  events ongoing on the last day  that the e -diary  was 
completed and record stop dates in the CRF.
Collect the e- diary  (if applicable).
Determine whether an y AEs (includes nonserious AEs, SAEs, and NDCMCs) h ave 
occurred since the previous visit and follow up on any  previousl y reported events to 
determine the outcome (ie, record stop dates or confirm if they  are still continuing) and 
record as described in Section 10.3, and record concomitant medications used to treat 
NDCMCs and SAEs.
Collect a blood sample of approximately  5 mL for immunogenicit y (a topi[INVESTIGATOR_634670]).
The investigator or a n authorized designee completes the CRF and the source documents.
8.10.5. Visit 5 (Dose 4 Visit, 365 to 
455Days of Age )
NOTE : If participants do not receive Dose 4 b y 20 April 2022, they  will be ineligible for 
Dose 4 and discontinued as per Section 7. As with all participants who are discontinued 
prior to Dose 4, the
parents/guardians should be encouraged to follow up wi th their primary  
care ph ysician to have the participant complete the pneumococcal conjugate vaccine series 
with commercial Prevnar [ADDRESS_847427] of care.
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and none of the temporary  
delay  criteria are met (Section 5.5).
Record nonstud y vaccinations administered since Visit 4, as described in 
Section 6.5.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 66Determine whether an y SAEs orNDCMCs have occurred since the previous visit and 
follow up on any previously reported events to determine the outcome (ie, record stop 
dates or confirm if they  are still continuing) and record as described in Section 10.3, and 
record concomitant medications used to treat NDCMCs and SAEs.
Measure and record the participant’s rectal temperature ( °C/°F).
Prior to vaccination, collect a blood sam ple of approximately  5 mL for immunogenicit y 
(a topi[INVESTIGATOR_634666]).
Administer a single 0.5 -mL injection of 20vPnC or 13vPnC into the left anterolateral 
thigh.
Administer concomitant vaccines containing measles, mumps, rubella ,and varicella
antigens and other permitted vaccines into a limb other than the site of 20vPnC or 
13vPnC injection , as appropriate for the age of the child and the route of vaccine 
administration (ie ,intramuscular, subcutaneous, or oral) ,and record the site of 
adminis
tration on the CRF.
After vaccination:
Site staff will observe the participant for [ADDRESS_847428] concomitant 
medications used to treat SAEs and NDCMCs.
Issue the participant’s parent(s)/legal guardian(s) an e -diary  (device or application).  
Provide instructions on use and completion of the e- diary .  Ask the participant’s 
parent(s)/legal guardian (s) to complete the e- diary from Day 1 to Day  7, with Day 1 
being the day  of vaccination.
Ask the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407408] 7 -day postvaccination period if the participant 
has a fever >40.0 °C (>104.0 °F), redness and/or swelling at the 20vPnC or 13vPnC 
injection site measuring >14 measuring device units (>7 cm), or severe 20vPnC or 
13vPnC injection site pain (causes limitation of limb movement), to determine if the 
event requires further assessment by  [CONTACT_36705].
Remind the participant’s parent(s)/legal guardian(s) to contact [CONTACT_407411] y significant illness or medical event 
(eg,emergency  room visit or hospi[INVESTIGATOR_059]) occurs during the stud y period.
Confirm whether the parent(s)/legal guardian(s) still possesses the participant contact 
[CONTACT_1137]. Provide a participant contact [CONTACT_634686].
CCI
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 67Remind the participant’s parent(s)/legal guardian(s) that the use of proph ylactic 
antipy retic/pain medica tion, while permitted, is not recommended on the day  of 
investigational product administration (before or after vaccination).
The investigator or an authorized designees completes the CRF and the source documents 
and updates the investigational product acc ountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
freque nt intervals for the 7 day s following vaccination to evaluate participant compliance 
and as part of the ongoing safet y review.
8.10.6. Visit 6 (Dose 4 Follow -up Visit, 28 to 42 Days After Dose 4)
NOTE :  Blood samples will be collected 
at this visit through [ADDRESS_847429] edby 
[CONTACT_756].
Ensure and document that the participant continues to be eligible for the study  
(seeSection 7.2 for participant discontinuation/withdrawal) and none of the temporary  
delay  criteria are met (Section 5.5).
Record nonstud y vaccinations administered since Visit 5, as described in Section 6.5.
Review the participant’s e -diary  data with the participant’s parent(s)/legal guardian(s); 
collect stop dates of an y e
-diary  events ongoing on the last day  that the e -diary  was 
completed and record stop dates in the CRF.
Collect the e- diary  (if device provi ded).
Determine whether an y AEs (includes nonserious AEs, SAEs, and NDCMCs) have 
occurred since the previous visit and follow up on any  previousl y reported events to 
determine the outcome (ie, record stop dates or confirm if they  are still continuing) and 
record as described in Section 10.3, and record concomitant medications used to treat 
NDCMCs and SAEs.
Collect a blood sample of appr oximately  5 mL for immunogenicit y (a topi[INVESTIGATOR_634670]).
The investigator or an authorized designee completes the CRF and the source documents.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 688.10.7. Visit 7 (Dose 4 6- Month Visit, 168 to 196 Days After Dose 4 )
NOTE:
For a participant with Visit 5 performed after 18Feb2022 through 14 Mar 2022, the 
window is 168 to 196 days after Visit 5, or until 02
Sep2022, whichever is earlier .
For a participant with Visit 5 performed on 15 Mar 2022 through 01Apr2022, the 
window for Visit 7 is 145 to 168 day s after Visit 5, or until 02
Sep2022, whichever is 
earlier .
For a participant with Visit 5 performed on 0 2Apr2022 through 20Apr2022, the 
window for Visit 
7is 126 to 145 day s after Visit 5, or until 02 Sep 2022, whichever is 
earlier .
Contact [CONTACT_2299]’s parent(s)/legal guardian(s) by  [CONTACT_85790]  
6months after the last study vaccination; this contact [CONTACT_407414] 1 study  vaccination, unless the participant’s
parent(s)/legal gua rdian(s) has withdrawn consent.
Determine whether an y SAEs and NDCMCs have occurred since the previous visit and 
follow up on an y previously reported events to determine the outcome (ie, record stop 
dates or confirm if they  are still continu ing) and record as described in Section 10.3, and 
record concomitant medications used to treat NDCMCs and SAEs.
The investigator or an authorized designee completes the CRF and the source documents.
8.10.8. Unscheduled Visits
If the participant’s parent(s)/legal guardian(s) reports redness or swelling at the injection site 
measuring >14 measuring device units (>7 cm), severe injection site pain ,or a fever >40.0°C 
(>104.0°F) during the [ADDRESS_847430] occur as soon 
as possible between the investigator or medicall y qualified designee and the participant’s 
parent(s)/legal guardian(s) to assess if an unscheduled investigator site visit is required.  Note 
that for a fever >40.0°C (>104.0°F), the participant’s parent(s)/legal guardian(s) should be 
instructed not to delay  seeking medical care, as appropriate, while arranging for an 
unscheduled visit if applicable.  A visit should be scheduled as soon as possible to assess the 
extent of the injection site reaction, unless an y of the following is true:
The participant’s parent(s)/legal guardian(s) is unable to bring the participant to the 
unscheduled visit.
The reaction is no longer present at the time of the telephone contact.
The participant’s parent(s)/l egal guardian(s) recorded an incorrect value in the e- diary  
(confirmation of an e -diary  data entry  error).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 69The principal investigator (PI) or authorized designee determined it was not needed.
This telephone contact [CONTACT_214356]’s source documentation and the 
CRF.
If the participant’s parent(s)/legal guardian(s) is unable to bring the participant to an 
unscheduled visit, or the PI  [INVESTIGATOR_214313], an y 
ongoing reactions must be assessed at the next st udy visit.
During the investigator site visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure rectal temperature ( °C/°F).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain in accordance with the grades provided in Section 8.2.2
(ifpresent).
Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The investigator or an authorized designee will complete the unsch eduled visit assessment 
page of the CRF.
The participant’s parent(s)/legal guardian(s) will also be instructed to contact [CONTACT_634687] y em ergency room visit or hospi[INVESTIGATOR_407374], drowsiness/ increased sleep, irritability , or local reaction within 7 day s of 
vaccination.
The participant’s parent(s)/legal guardian(s) will also be instructed to contact [CONTACT_407415] y significant illness, medical event, or hospi[INVESTIGATOR_240798].  The investigator site should determine if an unscheduled visit to further 
evaluate the event is warranted in all such cases.
Additionally , study  staff may  contact [CONTACT_2299]’s parent(s)/legal guardian(s) to obtain 
additional information on Grade 3 events entered into the e
-diary .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 709.STATISTICAL CONSIDERATIONS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
described here and further detailed in a statistical analy sis plan (SAP), which will be 
maintained by  [CONTACT_456].  The SAP may  modify  what is outlined in the protocol where 
appropriate; however, any  major modifications of the primary  endpoint definitions or their 
analyses will also be reflected in a protocol amendment.
9.1.Estimands an d Statistical Hypotheses
9.1.1. Estimands
The estimand corresponding to each primary , secondary ,  objective is 
described in the table in Section 3.  The estimands to evaluate the immunogenicity  objectives 
for noninferiority  are based on evaluable populations ( Section 9.3).  These estimands 
estimate the vaccine effect in the hypothetical setting where participants follow the study  
schedules and protocol requirements as directed. The estimand addresses the o
bjective of 
estimating the maximum potential difference between [ADDRESS_847431] of 
noncompliance is likely  to diminish the observed difference between the 2 groups. M issing 
serology  results will not be imputed. Immunogenicity  results that are below the LLOQ will 
be set to 0.5 × LLOQ in the anal ysis.
In the primary  safet y objective evaluations, missing e -diary  data will no t be imputed. 
Missing AE dates will be imputed according to [COMPANY_007] safet y rules. No other missing 
information will be imputed in the safet y anal ysis.
9.1.2. Statistical Hypotheses
[IP_ADDRESS]. Pneumococcal Immunogenicity Hypotheses
[IP_ADDRESS].1. Percentage of Participants With Predefined Pneumococcal Serotype -Specific 
IgG Concentration 1 Month After Dose 3 (Primary Pneumococcal Immunogenicity 
Objectives)
Hypothesis testing will be used to assess the noninferiorit y of 20vPnC to 13vPnC for
percentage s
of participants with predefined pneumococcal serot ype-specific IgG 
concentrations 1 month after Dose 3. The null hypothesis (H 0A) for a seroty pe is
H0A: π20vPnC –π13vPnC ≤ –10%,
with a 10% margin for noninferiority , where
π20vPnC is the percentage of participants achieving an IgG antibody  concentration of 
predefined level in the 20vPnC group for the seroty pe1 month after Dose 3 ;
If the serot ype is from th e 13 matched serot ypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, 23F ) in 13vPnC, π13vPnC is the percentage of participants achieving a
predefined IgG concentration level for the serot ypefrom the 13vPnC group 1 month after 
Dose 3 ;
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 71If the serot ype is from the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) in 
20vPnC , π13vPnC is the percentage of participants achieving a predefined IgG 
concentration level from the serot ype with the lowest percentage [ADDRESS_847432] that serot ype 3 behaves somewhat differently  from the other seroty pes in 
13vPnC ;therefore ,IgG results from serot ype 3 will not be used in the comparison to 
assess the noninferiority  of the 7 additional serot ypes.
The predefined levels for seroty pe-specific IgG concentrations are 0.35 µg/mL for all 
seroty pes in 20vPnC except that the predefined levels are 0.23 µg/mL , 0.10 µg/mL ,and 
0.12 µg/mL  for seroty pes 5, 6B, and 19A ,respectively .
The null hy pothesis (H 0A)will be rejected a nd noninferiority of 20vPnC to 13vPnC for the 
percentage of participants with predefined IgG concentration level will be declared for a 
seroty pe if the lower bound of the 2 -sided 95% CI for the difference (20vPnC –13vPnC) in 
percentages, based on the Miet tinen and Nurminen method, is greater than –10% (10% 
noninferiority margin).
[IP_ADDRESS].2. Pneumococcal Serotype -Specific IgG GMCs1 Month After Dose 4 (P rimary 
Pneumococcal Immunogenicity Objectives )
Hypothesis testing will be used to assess noninferiority  of 20vPnC to 13vPnC for
pneumococcal serot ype-specific IgG GMC s1 month after Dose 4. The null hy pothesis (H 0B)
for a seroty pe is
H0B: ln(µ20vPnC ) –ln(µ13vPnC ) ≤ln(0.5)
where ln(0.5) corresponds to a 2
-fold margin for noninferiority  and
ln(μ20vPn C)is the natural log of the geometric mean IgG concentration in the 20vPnC 
group forthat seroty pe1 month after Dose 4 ;
If the serot ype is from the 13 matched serot ypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, 23F ), ln(μ13vPnC ) isthenatural logofthegeometric mean IgG concentration in 
the 13vPnC group 1 month after Dose 4 ;
If the serot ype is from the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) in 
20vPnC , ln(μ13vPnC ) isthenatural logofthegeometric mean IgG concentration forthe 
seroty pe with the lowest IgG GMC [ADDRESS_847433] GMC in the 13vPnC group
will be used in the comparison. As stated in Section [IP_ADDRESS].1, historical data suggest that 
seroty pe 3 behaves 
somewhat differently  from the other serot ypes in 13vPnC ;therefore ,

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 72IgG results from seroty pe 3 will not be used in the comparison to assess the 
noninferiority  of the 7 additional seroty pes.
The null hy pothesis (H 0B)will be rejected and noninferiority  of 20vPnC to 13vPnC for the
pneumococcal serot ype-specific IgG GMC will be declared for a serot ype if the lower bound 
of the 2- sided 95% CI for the IgG GMR of 20vPnC t o 13vPnC is greater than 0.5 (2 -fold 
noninferiority  margin).
[IP_ADDRESS].3. Pneumococcal Serotype -
Specific IgG GMCs 1 Month After Dose 3(Key 
Secondary Pneumococcal Immunogenicity Objectives)
Hypothesis testing to assess noninferiorit y of 20vPnC to 13vPnC for pneumococcal
seroty pe-specific IgG GMC s1 month after Dose 3will be performed similarly  tothat for IgG 
GMC s
1month after Dose 4, as described in Section [IP_ADDRESS].2, with ln( μ20vPnC ) and ln( μ13vPnC ) 
being 
thenatural logofthegeometric mean IgG concentrations 1 month after Dose 3from the 
20vPnC and 13vPnC groups ,respectively . If the seroty pe is from the 7 additional seroty pes 
(8, 10A, 11A, 12F, 15B, 22F, 33F) in 20vPnC, ln(μ 13vPnC ) is the natural log of the geomet ric 
mean IgG concentration for the seroty pe with the lowest I gG GMC among the [ADDRESS_847434] GMC in the 13v PnC group will 
be used in th e hypothesis testing .
The null hy pothesis H 0Bwill be rejected and noninferiorit y of 20vPnC to 13vPnC for the
pneumococcal serot ype-specific IgG GMC will be declared for a serot ype if the lower bound 
of the 2- sided 95% CI for the IgG GMR of 20vPnC to 13vPnC for the seroty pe is greater 
than 0.5 (2- fold noninferiority  margin).
[IP_ADDRESS]. Concomitant Immunogenicity Hypotheses
[IP_ADDRESS].1. Noninferiority for Percentage of Partici pants With Prespecified Antibody 
Level to Each Concomitant Vaccine Antigen at 1 Month 
After Dose 3 (Primary 
Concomitant Immunogenicity Objectives)
Hypothesis testing to assess noninferiorit y of the 20vPnC group to the 13vPnC group for
percentage of partici pants with prespecified antibody  level to each concomitant vaccine 
antigen will be performed similarly  tothat for the percentage of participants with predefined 
seroty pe-specific IgG concentrations, as described in Section [IP_ADDRESS].1 , with π20vPn Cand 
π13vPn Cbeing thepercentages of participants with prespecified antibody  levels to diphtheria
toxoid, tetanus toxoid, pertussis antigens (PT, FHA, PRN), HBsAg , poliovirus strains ,or Hib 
at 1 month after Dose 3 from the 20vPnC and 13vPnC groups ,respectively .  The following 
are the prespecified antibody  thresholds for the concomitant vaccine antigens:
Antigen Prespecified Level
Diphtheria ≥0.1 IU/mL
Tetanus ≥0.1 IU/mL
Acellular pertussis (PT, FHA, PRN) ≥ the observed antipertussis antibody concentration 
achieved by 95% of 13vPnC recipi[INVESTIGATOR_840]

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 73Antigen Prespecified Level
Hepatitis B ≥10 mIU/mL
Poliomyelitis (types 1, 2 ,and 3) ≥1:8
Hib ≥0.15 µg/mL anti -PRP 
Alternative: ≥1.0 µg/mL anti -PRP
The null hy pothesis will be rejected and noninferiority  will be declared for a concomitant 
vaccine antigen if the lower bound of the 2 -sided 95% CI  for the difference 
(20vPnC –13vPnC) in percentages is greater than –10% (10% noninferiority  margin) for that 
concomitant vaccine antigen.
[IP_ADDRESS].2. Noninferiority for GMCs of Antibody Levels to Concomitant Vaccine Antigen 
at 1 Month 
After Dose 4 (Secondary Concomitant Immunogenicity Objectives)
Hypothesis testing to assess noninferiorit y of the 20vPnC group to the 13vPnC groupfor
GMCs of antibody  levels to each concomitant vaccine antigen 1 month after Dose 4 will be 
performed similarl y tothat for the pneumococcal seroty pe-specific IgG concentration, as 
described in Section [IP_ADDRESS].[ADDRESS_847435](µ 20vPnC ) and ln(µ 13vPnC ) being the natural logofthe
GMCs for antibody  levels to measles, mumps, rubella, and varicella virus esat 1 month after 
Dose 4 from the 20vPnC and 13vPnC groups, respectivel y.
The null hy pothesis will be rejected and noninferiority  will be declared for a concomitant 
vaccine antigen if the lower bound of the 2 -sided 95% CI  for GMR of the 20vPnC group to 
the13vPnC group is greater than 0.5 (2- fold noninferiorit y margin) for that concomitant 
vaccine antigen.
9.1.3. Multiplicity Considerations
Pneumococcal Immunogenicity Evaluation
For t he primary  pneumococcal immunogenicity  objective s comparing percentages of 
partic ipants with predefined serot ype-specific IgG concentration levels [ADDRESS_847436] as described in Section [IP_ADDRESS].[ADDRESS_847437] as
described in Section [IP_ADDRESS].2 at an alpha level of 0.05 for each serot ype. The primary  
pneumococcal immunogenicity  objectives willbe achieved if the noninferiority  of the IgG 
GMCs from the 20vPnC group compar edto the 13vPnC group at 1 month after Dose 4 is 
established for all 20 seroty pes.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847438] 
(Section [IP_ADDRESS].1) at an alpha level of 0.05 for each concomitant vaccine antigen. The 
primary  conco mitant immunogenicit y objective will be met if noninferiority is achieved for 
all concomitant vaccine antigens, diphtheria toxoid, tetanus toxoid, pertussis antigens (PT, 
FHA, PRN )
,HBsAg , poliovirus strains ,and Hib. Therefore, the t ype I error rate for the 
concomitant immunogenicity  assessment is well controlled at the 0.05 level .
Note that the noninferiority evaluations of concomitant immunogenicity  results comparing 
the 20vPnC group to the 13vPnC group are meaningf ul onl y ifthe criteria for achieving the 
pneumococcal immunogenicity  objectives are met. Consequently , there is no inflation in the 
type I error rate for the study , and no t ype I error adjustments are needed forthe concomitant 
immunogenicit y assessments .
9.2.Sample Size Determination
9.2.1. Sample Size Consideration for Primary Pneumococcal Immunogenicity 
Objective s
A total of approximately  2000 enrolled participants will y ield approximately  1600 evaluable 
participants assuming a 20% nonevaluable rate for the study ,resulting in approximately  
800evalu able participants foreach vaccine group with a 1:1 randomization ratio between the 
20vPnC and 13vPnC groups.  Sample size and power for the primary  pneumococcal 
immunogenicit y objectives associated with IgG conce ntration results at 1 month after Dose 3
and 1 month after Dose 4 are assessed based on simulations with assumptions supported by  
[CONTACT_634688] 2 infant study  of 20vPnC (B7471003) following 
multivariate log-normal distributions 
Assuming the true GMCs and variance -covariance matrices for the 20 seroty pe
-specific IgG 
concentrations from both 20vPnC and 13vPnC groups are the same as th oseobserved from 
Study  B7471003, with 800 evaluable participants from each vaccine group, the study  has 
approximately  93% probability  to show at least 3 7(out of 40 total) positive noninferiorit y 
assessments comparing IgG results between the 20vPnC and 13v PnC groups, 
based on 
percentages of participants with predefined serotype specific IgG concentration levels at 
1month after Dose 3 and seroty pe-specific IgG GMCs 1 month after Dose 4 for the 20 
seroty pes.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 76 
9.2.2. Sample Size Consideration for Concomitant Immunogenicity Objectives
For the primary  concomitant immunogenicity  objective s, Table 5presents the minimum 
evaluable sample size required to demonstrate noninferiority based on the percentage of 
participants with prespecified antibody  levels 1 month after Dose 3 with 10% noninferiorit y
margin for each concomitant v accine antigen.  Evaluable sample sizes needed to achieve 
99% power to detect noninferiority  for each antigen range from ~36 to ~367 per vaccine 
group .
Table 5.Sample Size Required With Specified Power to Demonstrate NI 
Comparing the 20vPnC Group to the 13vPnC Group Based on Percent age
of Participants With Prespecified Antibody Levels 1 Month After Dose 3 
for Concomitant Antigens, With an NI Margin of 10%
Antigen Antibody Level Threshold Assu med Percentageaof 
Participants With 
Prespecified Threshold 
ReachedSample Size per
Group With
20vPnC 13vPnC At Least 
95% 
PowerAt Least 
99% 
Power
Diphtheria ≥0.1 IU/mL 95 96 177 240
Tetanus ≥0.1 IU/mL 98 98 95 123
PT ≥ Concentration achieved by 
95% of 13vPnC group 94 95 201 276
FHA ≥ Concentration achieved by 
95% of 13vPnC group 95 95 155 212
PRN ≥ Concentration achieved by 
95% of 13vPnC group 93 95 266 367
Hepatitis B ≥10 mIU/mL 100 100 36 36
Polio 1 ≥1:8 100 100 36 36
Polio 2 ≥1:8 98 99 101 128
Polio 3 ≥1:8 100 100 36 36
Hib ( PRP) ≥0.15 µg/mL 98 98 95 123
Abbreviations: FHA = filamentous hemagglutinin; Hib = Haemophilus influenzae type b;
NI = noninferiority; PRN = pertactin; PRP = polyribosylribitol phosphate; PT = pertussis toxin.
Note : NIcriterion for each concomitant antigen :The lower bound of the 2-sided 95% CI for the difference 
betw een groups (20vPnC – 13vPnC) in thepercentage of participants with specified threshold is 
above –10%, calculated using the Miettinen and Nurminen method.
a.Differences betw een 20vPnC and 13vPnC are assumed to be similar to those observed between 13vPnC 
and Prevnar inPhase 3 Prevnar 13 Studies 6096A1 -004 and 6096A1 -3005.  Percentage sof participants 
with specified threshold sfor13vPnC are assumed to be the same as observed in the13vPnC groups in
Phase 3 Prevnar 13 Studies 6096A1 -004 and 6096A1 -3005.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 77 
 
 
 
For the secondary  concomitant immunogenicity  objective s, Table 6presents theminimum 
evaluable sample size required to demonstrate noninferiority based on the ratio of GMCs 
(GMRs) 1 month after Dose 4 with a 2
-fold margin for each c oncomitant vaccine antigen.  
Evaluable sample sizes needed to achieve 99% power to detect noninferiority  for each 
antigen range from ~2 0to ~[ADDRESS_847439] 
Deviation of GMRa(on 
the Natural Log Scale)Sample Size per 
Group With
At Least
95% PowerAt Least
99% Power
Measles 0.98 0.654 26 36
Mumps 1.00 0.743 31 44
Rubella 0.83 1.294 171 240
Varicella 1.00 0.497 15 20
Abbreviations: GMC = geometric mean concentration; GMR = geometric mean ratio; 
NI = noninferiority.
Note : NIcriterion for each antigen :The lower bound of the 2-sided 95% CI for the GMR (20vPnC to 13vPnC) 
is greater than 0.5, calculated using a t-distribution.
a.GMRs and standard deviations are obtained from an internal study (6096A1 -004) for all antigens.
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 789.3.Populations for Analysis
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who have a signed ICD.
Randomized All participants who are assigned a randomization number in the 
IWR sy stem.
Dose 3 evaluable 
immunogenicit yAll eligible randomized participants who are 42 to 98 day s of age 
(inclusive) on the day of first vaccination, receive the vaccines to 
which they  are randoml y assigned at the first [ADDRESS_847440] 1 
valid and determinate immunogenicit y result from 1 mon th after 
Dose 3 visit (Visit 4), have blood collection within an appropriate 
window after Dose 3, and have no other major protocol deviations 
as determined b y the clinician.
Dose 4 evaluable 
immunogenicit yAll eligible randomized participants who are 42 t o 98 day s of age 
(inclusive) on the day  of first vaccination, receive all 4 randomized 
vaccin ations, with Dose 4 received within the defined window 
(365-455 day s of age), have at least [ADDRESS_847441] safet y data assessed after an y dose.
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock for an y of the planned 
analyses in Section 9.5.1.  I t will describe the participant populations to be included in the 
analyses and the procedures for accounting for missing, unused, and spurious data.  This 
section provides a summary  of the planned statistical anal yses of the primary , secondary ,  
 endpoints.
9.4.1. Immunogenicity Analyses
The statistical anal ysis of pneumococc al immunogenicity  results will be primarily  based on 
the evaluable immunogenicity  populations as defined in Section 9.3.  The statistical analy sis 
of co ncomitant immunogenicity
 results will be primarily  based on the evaluable 
immunogenicit y populations among those who receive the appropriate concomitant vaccines.
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 79 
Participants will be summarized according to the vaccine group to which they  were 
randomi zed.
Endpoint Statistical Analysis Methods
Primar y 
pneumococcal 
immunogenicit yPercentages of participants with predefined pneumococcal 
serotype -specific IgG concentrations 1 month after Dose 3
For each of the 20 serot ypes, the difference between groups
(20vPnC –13vPnC) and its CI for the percentage of participants 
with predefined serot ype-specific IgG concentrations [ADDRESS_847442] fo r 
noninferiority  of 20vPnC to 13vPnC as detailed in 
Section [IP_ADDRESS].1.
The anal ysis will be based on the Dose 3 evaluable 
immunogenicit y popula tion.  
 
 
Participants will be 
summarized according to the vaccine group to which they  were 
randomized. Missing serology  data will not be imputed.
GMRs of pneumococcal s erotype -specific IgG concentrations 
from the 20vPnC group to the 13vPnC group 1 month after 
Dose 4
For each of the 20 serot ypes, the GMR of 20vPnC to 13vPnC at 
1month after Dose 
4will be provided. If a serot ype is from the 13 
matched serot ypes, the IgG GMC for the serot ype in the 20vPnC 
group will be compared with the IgGGMC for that serot ype in the 
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847443] GMC in the 13vPnC group will be used in the comparison. 
GMRs and their 2- sided 95% CIs will be derived by  [CONTACT_634689] s on the n atural log scale of the 
concentration based on the t-distribution, and then exponentiating 
the results. The difference in means, on the natural log scale, will 
be 20vPnC minus 13vPnC. The lower limit of the CI  will be used 
in the hy pothesis test for noni
nferiority  of 20vPnC to 13vPnC as 
detailed in Section [IP_ADDRESS].2.
The anal ysis will be based on the Dose 4 evaluable 
immunogenicit y population.   
 
 
Participants will be summarized according to the vaccine group to 
which they  were randomized.  Missing serology  data will not be 
imputed.
Primary  
concomitant 
immunogenicit yPercentages of participants with prespecified antibody levels to 
concomitant vaccine antigen 1 month after Dose 3
For each concomitant vaccine antigen,
a.Antibody  levels to diphtheria toxoid, tetanus toxoid, and 
pertussis antigens (PT, FHA, PRN) ,
b.Antibody  levels to HBsAg,
c.Antibody  levels to poliovirus strains ( types 1, 2, and 3),
d.Antibody  levels to Hib,
The difference between groups (20vPnC 
–13vPnC) and its 2- sided 
95% CI for the percentage of participants with prespecified 
antibody  levels [ADDRESS_847444] for assessing the 
noninferiority  of the 20vPnC group to the 13vPnC group as 
detailed in Section [IP_ADDRESS].1.
The anal ysis will be based on the Dose 3 evaluable 
immunogenicit
y population, restricted to those who also receive 
the corresponding concomitant vaccines.  
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 81Endpoint Statistical Analysis Methods
 
 
 
 
 
Participants will be summarized 
according to the vaccine group to which they  were randomized. 
Missing serology  data will not be imputed.
Key secondary  
pneumococcal 
immunogenicit yGMRs of pneumococcal serotype -specific IgG concentrations 
from the 20vPnC group to the 13vPnC group 1 month after 
Dose 3
Seroty pe-specific IgG concentrations 1 month after Dose 3 will be 
analyzed similarl y to the serotype -specific IgG concentrations 
1 month af ter Dose 4.  Hy pothesis testing for noninferiorit y of 
20vPnC to 13vPnC will be performed as described in 
Section [IP_ADDRESS].3.
The anal ysis will be based on the Dose 3 evaluable 
immunogenicit y population.   
 
 
Participants will be summarized according to the vaccine group to 
which they  were randomized.  Missing serology  data will not be 
imputed.
Secondary  
pneumococcal 
immunogenicit yPneumococcal serotype -specific OPA GMTs
For each of the 20 serot ypes, GMTs and 2-sided 95% CI s for 
pneumococcal serot ype-specific OPA titers at 1 month after Dose 
3, prior to Dose 4, and 1 month after Dose 4 will be provided for 
each group. Geometric means and the associated 2 -sided CI s will 
be derived b y calculating means and CIs on the natural log scale 
based on the t -distribution, and then exponentiating the results.
Percentages of participants with predefined pneumococcal 
serotype -specific IgG concentrations 1 month after Dose 4
For eac h of the 20 serot ypes, the percentage (and2-sided 95% CI)
of participants with the predefined serot ype-specific IgG 
concentration level 1 month after Dose 4 will be provided for each 
vaccine group. The Clopper -Pearson method will be used to 
calculate the CIs.
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 82Endpoint Statistical Analysis Methods
GMFRs of pneumococcal s erotype -specific IgG concentrations
GMFRs and 2-sided 95% CIs for serot ype-specific IgG 
concentrations from 1 month after Dose 3 to before Dose 4, from 
before Dose 4 to 1 month after Dose 4, and from 1 month after 
Dose 3 to 1 
month after Dose 4 will be provided for each vaccine 
group. GMFRs will be limited to participants with nonmissing 
values at both time points. The GMFR will be calculated as the 
mean of the difference of logarithmicall y transformed assay  results 
(later ti me point – earlier time point) and transformed back to the 
original scale. Two-sided 95% CIs will be obtained by  [CONTACT_634690]’s t -distribution for the mean difference of the 
logarithmicall y transformed assay  results and transforming the 
limits back to the original scale.
Secondary
concomitant 
immunogenicit yPercentages of participants with alternative antibody levels to 
concomitant vaccine antigen at 1 month after Dose 3
Percentages ( and Clopper -Pearson 2-sided 95% CI s)of 
participants wi th alternative prespecified antibod y levels to Hib at 
1 month after Dose 3 will be provided for each vaccine group. 
Differences between groups (20vPnC – 13vPnC) in these 
percentages and the associated Miettinen and Nurminen CI s will 
be calculated.
GMRs of antibody levels to measles, mumps, rubella, and 
varicella viruses from the 20vPnC group to the 13vPnC group 
1 month after Dose 4
For each antibod y level to measles, mumps, rubella, and varicella 
viruses, the GMR of the 20vPnC group to the 13vPnC group at 
1month after Dose 4 will be provided. GMRs and their 2 -sided 
95% CI s will be derived by  [CONTACT_634691] t- distribution, and then 
exponentiating the results. The difference in means, on the n atural 
log scale, will be 20vPnC minus 13vPnC. The lower limit of the 
CI will be used in the hypothesis test for noninferiority  of the 
20vPnC group to the 13vPnC group as detailed in 
Section [IP_ADDRESS].2.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 83 
  
 
  
 
 
 

 
 
 
 
  
 
 
 
  
 
 
 

 
 
CCI
CCI
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 84  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

 
9.4.2. Safety Analyses
Endpoint Statistical Analysis Methods
Primary  Descriptive statistics will be provided for each reactogenicity  endpoint 
for each dose and vaccine group. Local reactions and sy stemic events 
from Day  1 through Day  7 after each vaccination will be presented b y 
severit y cumulativel y across severity levels. Descriptive summary  
statistics will include counts and percentages of participants with the 
indicated endpoin t and the associated Clopper -Pearson 95% CI s. 
Between -group differences (20vPnC – 13vPnC) in these percentage sand 
their 2- sided 95% CIs will also be provided.  The Miettinen and 
Nurminen method will be used to derive the 95% CI  for the difference in 
percentages between vaccine groups.
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 85Endpoint Statistical Analysis Methods
AEs will be categorized according to Medical Dictionary  for Regulatory  
Activities (MedDRA) terms. A 3-tier approach will be used to 
summarize AEs. Under this approach AEs are classified into 1 of 3 tiers: 
(1) Tier [ADDRESS_847445]’s safet y review plan; (2) Tier 2 events 
are those that are not Tier 1 but are considered “relatively common”;
aMedDRA preferred term is defined as a Tier [ADDRESS_847446] 
1% of participants in at least 1vaccine group reporting the event; and (3) 
Tier 3 events are those that are neither Tier 1 nor Tier 2 events. For both 
Tier 1 and Tier 2 events, the 95% CI s for the difference in percentage of 
participants reporting the events between the 20vPnC and 13vPnC groups 
will be calculated using the Miettinen and Nurminen method. In 
addition, for Tier [ADDRESS_847447] statistic is 
asymptoticall y normall y distributed. There is no Tier 1 event identified 
for 20vPnC at this stage. Descriptive summary  statistics (counts,
percentages ,and associated Clopper -Pearson 95% CI s) will be provided 
for Tier 3 events for each vaccine group.
SAEs and NDCMCs will be categorized according to MedDRA terms. 
Counts, percentages, and the associated Clopper -Pearson 95% CIs for
SAEs and NDCMCs from Dos e 1 to 6 months after Dose 4 will be 
provided for each vaccine group.
The safet y analyses are based on the safet y population. Participants will 
be summarized by  [CONTACT_634692]. Missing e -diary data will not be 
imputed; missing AE dates will be handled according to the [COMPANY_007] safety 
rules.
Secondary Not applicable (N/A)
9.4.3. Other Analyses 
None.
9.5.Interim Analyses
No interim anal ysis is planned in this study . Statistical anal yses will be carried out when the 
final data for the specified anal yses are available .
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 869.5.1. Analysis Timing
Statistical analy ses will be carried out with all available data when :
Primary  analysis: complete safet y and immunogenicity  data are avai lable through 
1month after Dose 4;
Final anal ysis: compl ete safet y data are available through the visit occurring [ADDRESS_847448] participant completes the final 
visit telephone call. Laboratory  personnel performing the assay
s will remain blinded until all 
assay s are completed.
 
 
 
 
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 8710. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. A ppendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol , protocol amendments, ICD, IB, and other relevant documents 
(eg,advertisements) must be reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendme nts to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providi ng written summaries of the status of the study  to the IRB/EC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by [CONTACT_1744]/EC 
procedures;
Providing oversight of the conduct of the stud y at the site and adherence to requirements 
of 21 Code of Federal Regulations (CFR), ICH guidelines, the I RB/EC, European 
regulation 536/2014 for clinical studies (if applicable), and all other applicable local 
regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately.
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgen t safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 88of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant’s parent(s)/legal guardian(s) and answer all questions regarding the study .
The participant’s parent(s)/legal guardian(s) must be informed that their participation is 
voluntary .  The participant’s parent(s)/legal guardian(s) will be requir ed to sign a statement 
of informed consent that meets the requirements of [ADDRESS_847449] (HI PAA) requirements, 
where applicable, and the I RB/EC or study  center.
The investig ator must ensure that each study  participant’s parent(s)/legal guardian(s) is full y 
informed about the nature and objectives of the study , the sharing of data related to the study , 
and possible risks associated with participation, including the risks assoc iated with the 
processing of the participant’s personal data.
The participant’s parent(s)/legal guardian(s) must be informed that the participant’s personal 
study -related data will be used by  [CONTACT_10999].  
The l evel of disclosure must also be explained to the participant’s parent(s)/legal guardian(s).
The participant’s parent(s)/legal guardian(s) must be informed that the participant’s medical 
records may  be examined by  [CONTACT_17080] y Assurance auditors or othe r authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  [CONTACT_78273].
The investigator further must ensure that each study  participant’s parent(s)/legal guardian(s) 
is fully  informed about his or her right to access and correct the participant’s personal data 
and to withdraw consent for the processing of the participant’s personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was en rolled in the study  and the date the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICD.
The participant’s parent(s)/legal guardian(s) must be reconsented to the most current version 
of the I CD(s) dur ing the participant’s participation in the study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 89A cop y of the ICD(s) must be provided to the participant’s parent(s)/legal guardian(s).
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organ izational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data , participants will be assigned a single, participant- specific numerical code.  
Any participant records or data sets that are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred.  All other identifiable dat a 
transferred to the sponsor will be identified by  [CONTACT_20007], participant -specific code.  The 
study  site will maintain a confidential list of participants who participated in the study , 
linking each participant’s numerical code to his or her actual ident ity.  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study
 agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to pub licly disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable l ocal laws/regulations.  I n addition, [COMPANY_007] reports study  results outside of the 
requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, bala nced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  The r esults are 
generall y submitted for posting in accordance with the format and timelines set for th by  [CONTACT_116483].

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847450] for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009] .
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (clinical study  report [ CSR ]synopses in which any  
data that could be used to identify  individual participants have been removed) on 
www.pfizer.com for [COMPANY_007]- sponsored interventional studies at the same time the 
corresponding stud y results are posted to www.clinica ltrials.gov.
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.  Clinical data, under Phase 1 of this
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Phase 2 of this policy , includes the publishing of individual partic ipant data.  Policy  
0070 applies to new marketing authorization applications submitted via the centralized 
procedure since 01 January 2015 and applications for line extensions and for new indications 
submitted via the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class.  [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requestin g access for commercial/competitive or legal purposes.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 9110.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit stud y-related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant person nel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and m itigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the 
monitoring plan.
Thesponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_217668], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all a pplicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_847451] en sure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 92The investiga tor(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection an d will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.   The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and com ment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may
 need to request previous medical records or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in the I SF.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any 
time for an y reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion.  A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organization (CRO) if requested to do so by  [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract a nd this protocol, the contract will control as to termination rights.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 9310.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 18 months after end of the stud y 
(or study  termination), whichever comes first.
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
interventio n-related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and author ship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements.
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this se ction will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately
 qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_31037] I SF.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, the participant ’sparent(s)/legal guardian(s) are provided with a 
contact [CONTACT_1137].  The contact [CONTACT_4662], at a minimum, protocol and investigational product 
identifiers, particip ant numbers, contact [CONTACT_22850], and contact 
[CONTACT_4664] a contact [CONTACT_214362] a medical question or problem originating from another healthcare 
professional not involved in the participant’s participation in the study .  The contact [CONTACT_107101] b y investigator staff if they are seeking advice on medical questions or 
problems; however, it should be used only  in the event that the established communication 
pathway s between the investigator site and the study  team are not available.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847452] number is not intended for use b y the participant ’s 
parent(s)/legal guardian(s) directl y, and if a participant ’s parent(s)/legal guardian(s) calls that 
number, he or she will be directed back to the investigator site.
10.2. Appendix 2: Clinical Laboratory Tests
Not applicable.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 9510.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical o ccurrence in a patient or clinical study  participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, electrocardiogram [ ECG ], radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (ie, not related to 
progression of underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the c ondition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or t he clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.  Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent.  Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as an AE or SAE if they
 fulfill the definition of an AE or SAE.  Also, “lack of 
efficacy ” or “failure of expected pha rmacological action” constitutes an AE or SAE.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 96Events NOT Meeting the AE Definition
Events that, in the clinical judgment of the investigator, are 1) consistent with normal 
growth and development and 2) do not differ significantly  in frequency  or severit y from 
expected are not generally  to be considered AEs. Examples may  include, but are not 
limited to, teething, contact [CONTACT_407422], spi[INVESTIGATOR_322054], colic, or typi[INVESTIGATOR_407372]/cry ing in 
infants and children.
Any clinica lly significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder bein g studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads 
to the proc edure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of an NDCMC
An NDCMC is defined as a significant disease or medical condition, not previously  
identified, that is expected to be persistent or is otherwise long -lasting in its effects.
10.3.3. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that , at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event.  I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 97c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually involving 
at least an overnight stay) at t he hospi[INVESTIGATOR_294504]/or 
treatment that would not have been appropriate in the phy sician’s office or outpatient 
setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a complication 
prolongs hospi[INVESTIGATOR_634671], the event is serious.  When in 
doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be 
considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen fr om 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e.Is acongenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_160340].  These events should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  or 
drug abuse.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 9810.3.4. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Vaccine SAE Reporting Form to [COMPANY_007] Safety .  
These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) nonserious AEs; and 
(3) exposure to the investigational product under study  during pregnancy  or breastfeeding, 
and occupational exposure.
It should be noted that the Vaccine SAE Reporting Form for reporting of SAE information 
is not the same as the AE page of the CRF .  When the same data are collected, the forms 
must be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE 
Reporting Form for reporting of SAE i nformation.
Safety Event Recorded on the CRF Reported on the Vaccine 
SAE Reporting Form to 
[COMPANY_007] Safety Within 
[ADDRESS_847453] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP] 
supplemental form for 
EDP)
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to [COMPANY_007] Safety  in lieu of completion of the Vaccine SAE Reporting 
Form /AE/SAE CRF page.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 99There may  be instances when copi[INVESTIGATOR_404205] y.  In this case, all participant identifiers, with the exception of the 
participant number , will be redacted on the copi[INVESTIGATOR_404204] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis ( not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE that is assessed as 
severe should not be confused with an SAE.  Severe is a category  utilized for rating the 
intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
GRAD
E If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, or SEVERE to describe the maximum 
intensity  of the AE. For purposes of consistency , these intensity  grades are 
defined as follows:
1 MILD Does not interfere with participant's usual function.
2 MODERATE Interferes to some extent with participant's usual 
function.
3 SEVERE Interferes significantl y with participant's usual 
function.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 100Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention and 
each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
product s, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the sponsor.  However, it is very 
important that the investigator always make an assessment of causality for every 
event b efore the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  assessment.
The causality  assessment is on e of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational product caused the 
event, then the event will be handled as “related to investigational product” for reporting 
purposes, as defined b y the sponsor.  In addition, if the investigator determines that an 
SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the Vaccine SAE Reporting Form and in accordance with the SAE 
reporting requirements.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 101Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_215867]/or causalit y of the AE or SAE as fully as possible.  This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other h ealthcare professionals.
If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide [COMPANY_007] Safety  with a copy  of an y postmortem 
findings including histopathology .
New or updated informatio n will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.
10.3.5. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event with in 24 hours.
The site will enter the SAE data into the electronic system as soon as the data become 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or chan ges to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a paper SAE form (see next section) 
or to [COMPANY_007] Safety  by [CONTACT_756].
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 102SAE Reporting to [COMPANY_007] Safety via Vaccine SAE Reporting Form
Facsimile transmission of the Vaccine SAE Reporting Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the Vaccine SAE Reporting Form sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Reporting Form pages within the designated 
reporting time frames.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 104 
 
 
 
 
 
 
 
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: L iver Safety: Suggested Actions and Follow -up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show tra nsient liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver inj ury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptib le.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a 
participant presents with clinical signs/s ymptoms, such LFT results should be managed and 
followed as described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  [CONTACT_74097].  The increase i n TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory  
sample).  In rare instances, by  [CONTACT_22858], AST/AL T values might 
have decreased .  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway sbe 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value >2 ×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT values 
>
2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is smaller).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 106Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 ×ULN 
(whichever is smal ler).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_847454] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time/internati onal 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter me dications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted.
All cas es demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy ’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
10.7. Appendix 7: ECG Findings of Potential Clinical Concern
Not applicable .
CCI

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, Serious 
Adverse Events, and Dev ice Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definitions of a Medical Device Incident
The definitions and procedures detailed in this appendix are in accordance with I SO [ZIP_CODE].
Both the investigator and the sponsor will comply  with all local medical device reporting 
requirements.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.[ADDRESS_847455] of sponsor 
medical devices).
10.8.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined as an y untoward medical occurrence, unintended disease or injury , 
or untoward clinical signs (including abnormal laboratory  finding) in study  
participants, users, or other persons, whether or not related to the investigational 
medical device.  This definition includes events related to the investigatio nal 
medical device or comparator and events related to the procedures involved except 
for events in users or other persons, which only  include events related to 
investigational devices.
An ADE is defined as an adverse event related to the use of an investi gational 
medical device.  This definition includes any adverse events resulting from 
insufficient or inadequate instructions for use, deployment, implantation, 
installation, or operation, or an y malfunction of the investigational medical device as 
well as an y event resulting from use error or from intentional misuse of the 
investigational medical device.
10.8.2. Definition of SAE, SADE, and Unanticipated Serious Adverse Device Effect
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 108An SAE is an AE that:
a.Led to death.
b. Led to serious deterioration in the health of the participant, that either resulted in:
A life -threatening illness or injury .  The term “life -threatening” in the definition of 
serious refers to an event in which the participant was at risk of death at the time of 
the event.  It does not refer to an event that hy pothetically  might have caused death, 
if it were more severe.
A permanent impairment of a bod y structure or a body function.
Inpatient or prolonged hospi[INVESTIGATOR_059].  Planned hospi[INVESTIGATOR_272] a preexisting 
condition, or a procedure required b y the protocol, without serious dete rioration in 
health, is not considered an SAE.
Medical or surgical intervention to prevent life- threatening illness or injury  or 
permanent impairment to a body  structure or a body  function.
c.Led to fetal distress, fetal death, or a congenital abnormality  or birth defect.
SADE Definition
An SADE is defined as an adverse device effect that has resulted in an y of the 
consequences characteristic of a serious adverse event.
[LOCATION_003]DE Definition
A [LOCATION_003]DE is a serious adverse device effect which by  [CONTACT_5942], incidence, 
severit y, or outcome has not been identified in the current version of the risk 
analysis management file.
10.8.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its identity , 
quality , durabilit y, reliability , safet y, or performance.  Device deficiencies include 
malfunctions, use errors, and inadequate labeling.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8.4. Recording/Reporting and Follow -up of A Es and/or SAEs and Device 
Deficiencies
AE, SAE, and Device Deficiency Recording
When an AE/SAE/device deficiency  occurs, it is the responsibility  of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  
reports, and diagnostic reports) related to the event.
The investigator will then record all relevant AE/SAE/device deficiency  information 
in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice and on the appropriate form o f the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of following the reporting process described 
in the I P manual.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
For device deficiencies, it is very  important that th e investigator describes any  
corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of a device 
deficiency .  This includes any  amendment to the device design to prevent 
recurrence.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE/SAE/device deficiency  
reported during the stud y and assign it to 1 of the following categories:
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as sever e.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 110An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between study  intervention 
and each occurrence of each AE/SAE/device deficiency .
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administrati on will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE/device deficiency , the investigator must document in the medical 
notes that he/she h as reviewed the AE/SAE/device deficiency and has provided an 
assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE/SAE/Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE/SAE/device deficiency  as 
fully  as possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations or consultation with other healthcare providers.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 111If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide [COMPANY_007] Safety  with a cop y of any postmortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.
10.8.5. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data co llection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via Vaccine SAE Report ingForm
Facsimile transmission of the Vaccine SAE Report ingForm is the preferred method 
to transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the Vaccine SAE Report ingForm sent by  [CONTACT_407423].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report ingForm pages within the designated 
reporting time frames.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8.6. Reporting of SADEs
SADE Reporting to [COMPANY_007] Safety 
NOTE: There are additional reporting obligations for medical device incidents that are 
potentially  related to SAEs that must fulfill the legal responsibility to notify  appropriate 
regulatory  authorities and other entities about certain safet y information r elating to medical 
devices being used in clinical studies.
Any device deficiency  that is associated with an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing whether they  could have led to an SAE.  These shall be reported to the 
regulatory  authorities and I RBs/ECs as required by  [CONTACT_2091].
10.9. Appendix 9: Country -Specific Requirements
Not applicable .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].10. Appendix 10: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
7vPnC 7-valent pneumococcal conjugate vaccine
13vPnC 13-valent pneumococcal conjugate vaccine
20vPnC 20-valent pneumococcal conjugate vaccine
ADE adverse device effect
AE adverse event
ALT alanine aminotransferase
AOM acute otitis media
AST aspartate aminotransferase
CAP community -acquired pneumonia
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CONSORT Consolidated Standards of Reporting Trials
CLIA chemiluminescent immunoassay
CRF case report form
CRM [ADDRESS_847456] European Clinical Trials Database
FDA Food and Drug Administration
FHA filamentous hemagglutinin
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847457]
HIV human immunodeficiency virus
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IgG immunoglobulin G
IND investigational new drug
INR international normalized ratio
IP manual investigational product manual
IPD invasive pneumococcal disease
IRB institutional review board
IRT interactive response technology
ISF investigator site file
ISO International Organization for Standardization
IU international units
IWR interactive Web -based response
LFT liver function test
LLOQ lower limit of quantitation
MedDRA Medical Dictionary  for Regulatory  Activities
MMR measles, mumps ,and rubella vaccine
N/A not applicable
NA neutrali zing antibod y
NDCMC newly  diagnosed chronic medical condition
NI noninferiority
OPA opsonophagocy tic activity
PCD primary  completion date
PI [INVESTIGATOR_407377]23 23-valent pneumococcal poly saccharide vaccine
PRN pertactin
PRP polyribos ylribitol phosphate
PT pertussis toxin
SADE serious adverse device effect
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847458]
VT vaccine -type
WHO World Health Organization

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1Said MA, Johnson HL , Nony ane BA, et al. Estimating the burden of pneumococcal 
pneumonia among adults: a sy stematic review and meta -analysis of diagnostic 
techniques. PL oS One 2013;8(4):e60273.
2O'Brien KL, Wolfson L J, Watt JP, et al. Burden of disease caused by  
[CONTACT_634693] 5 years: global estimates. Lancet
2009;374(9693):893- 902.
3Huang SS, Johnson KM, Ray  GT, et al. Healthcare utilization and cost of pneumo coccal 
disease in the [LOCATION_002]. Vaccine 2011;29(18):3398-412.
4Iyer AS, Ohtola JA, Westerink MAJ. Age -related immune response to pneumococcal 
polysaccharide vaccination: lessons for the clinic. Expert Rev Vaccines 2015;14(1):
85-97.
5Wahl B, O’Brien KL, Greenbaum A, et al. Global burden of Streptococcus pneumoniae 
in children y ounger than 5 y ears in the pneumococcal conjugate vaccines (PCV) era: 
2000- 2015. 10th I nternational Sy mposium on Pneumococci & Pneumococcal Diseases 
(IS[COMPANY_003] -10); 
26-30 Jun 2016; Glasgow, Scotland.
6Moore MR, L ink-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal 
conjugate vaccine in children on invasive pneumococcal disease in children and adults 
in the [LOCATION_003]: analy sis of multisite, population -based surveillance. Lancet Infect Dis
2015;15(3):301 -9.
7Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non -vaccine seroty pes 
causing invasive pneumococcal disease in England and Wales, 2000 –17: a prospective 
national observational cohort study .Lancet Infect Dis 2018;18:441
-51.
8European Centre for Disease Prevention and Control. I nvasive pneumococcal disease. 
In: ECDC. Annual epi[INVESTIGATOR_93282] 2017. Stockholm: ECDC ; 2018. Available 
from : https://www.ecdc.europa.eu/sites/ default /files/ documents/AER_for_2017 -
invasive -pneumococcal -disease.pdf . Accessed [ADDRESS_847459] Dis 
2015;61(5):767 -75.
10Stockmann C, Ampofo K, By [CONTACT_407425] , et al. Pneumococcal meningitis in children:  
epi[INVESTIGATOR_623] , seroty pes, and outcomes from 1997 -2010 in Utah. Pediatrics 
2013;132(3):421 -8.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847460], et al. Invasive pneumococcal disease in children’s 
hospi[INVESTIGATOR_600]: 2014–2017. Pediatrics 2019;144(3):e20190567.
12JainS, Williams DJ, Arnold SR, et al. Community -acquired pneumonia requiring 
hospi[INVESTIGATOR_287691] U.S. children. N Engl J Med 2015;372(9):835-45.
13JainS, Self WH, Wunderink RG, et al. Community- acquired pneumonia requiring 
hospi[INVESTIGATOR_287691] U.S. adults. N Engl J Med 2015;373(5):415 -27.
14Griffin MR, Zhu Y, Moore MR, et al. U.S. hospi[INVESTIGATOR_407379] a decade 
of pneumococcal vaccination. N Engl J Med 2013;369(2):155-63.
15Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media –related health care use in 
the [LOCATION_002], 2001 -2011. JAMA Pediatr 2014;168(1):68 -
75.
16Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their t ypes: past, 
present, and future. Clin Microbiol Rev 2015;28(3):871 -99.
17Hausdorff WP, Hanage WP. I nterim results of an ecological experiment— conjugate 
vaccination against the pneumococcus and serot ype replacement. Hum Vaccin
Immunother 2016;12(2):358-74.
18AlonsoDeVelasco E, Verheul AFM, V erhoef J, et al. Streptococcus pneumoniae : 
virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59(4):591 -603.
19Centers for Disease Control and Prevention. Prevention of pneumococcal disease: 
recommendations of the Advisory  Committee on Immun
ization Practices (ACI P). 
MMWR Recomm Rep 1997;46(RR- 8):1-24.
20Austrian R. A brief history  of pneumococcal vaccines. Drugs Aging 1999;15(Suppl 
1):1-10.  
21Shapi[INVESTIGATOR_5539], Berg AT, Austrian R, et al. The protective efficacy  of poly valent 
pneumococcal polysaccharide vaccine. N Engl J Med 1991;325(21):1453-60.
22Stein KE. Thy mus- independent and thy mus- dependent responses to pol ysaccharide 
antigens. J I nfect Dis 1992;[ADDRESS_847461] 1:S49 -S52.
23Borrow R, Health PT, Siegrist CA. Use of pneumococcal polysacchari de vaccine in 
children: what is the evidence? Curr Opin I nfect Dis 2012;25(3):292 -303.
24Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal pol ysaccharide 
vaccine in older adults. N Engl J Med 2003;348(18):1747 -55.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, [ADDRESS_847462] invasive disease and hospi[INVESTIGATOR_307] -treated 
pneumonia among people aged ≥65 years: a retrospective case -control study . Clin Infect 
Dis2015;60(10):[ADDRESS_847463] Dis 1981;[ADDRESS_847464]:S108 -S112.
27Torres A, Bonanni P, Hryniewicz W, et al. Pneumococcal vaccination: what h ave we 
learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis
2015;34(1):19 -
31.
28Robinson KA, Baughman W, Rothrock G, et al. Epi[INVESTIGATOR_407380], 1995 -1998: opportunities for 
prevention in the conjugate vaccine era. JAMA 2001;285(13):[ADDRESS_847465] invasive disease: implications for conjugate vaccine formulation and use, part I. 
Clin Infect Dis 2000;30(1):100 -21.
30Hausdorff WP, Bry ant J, Kloek C, et al. The contribution of specific pneumococcal 
serogroups to different disease manifestations: implications for conjugate vaccine 
formulation and use, part II. Clin I nfect Dis 2000;30(1):1 22-40.
31Nuorti JP, Whitney  CG. Prevention of pneumococcal disease among infants and 
children 
-use of 13-valent pneumococcal conjugate vaccine and 23- valent 
pneumococcal poly saccharide vaccine -recommendations of the Advisory  Committee 
on Immunization Pr actices (ACI P). MMWR Recomm Rep 2010;59(RR -11):1-18.
32Johnson HL , Deloria -Knoll M, L evine OS, et al. Sy stematic evaluation of seroty pes 
causing invasive pneumococcal disease among children under five: the Pneumococcal 
Global Seroty pe Project. PLoS Med 2010;7(10):[ADDRESS_847466] Dis
2013;19(7):[ADDRESS_847467] Dis J 2002;21(9):810-5.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 11935Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal 
conjugate vaccine in children y ounger than 5 y ears of age for prevention of pneumonia: 
updated anal ysis using World Health Organization standardized interpretation of chest 
radiographs. Pediatr Infect Dis J 2006;25(9):[ADDRESS_847468] pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double -blind, placebo -controlled trial. Lancet2005;365(9465):1139-46.
37Eskola J, Ki lpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against 
acute otitis media. N Engl J Med 2001;344(6):403 -9.
38O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safet y of seven -valent conjugate 
pneumococcal vaccine in American Indian c hildren: group randomised trial. Lancet 
2003;362(9381):355-61.
39Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal 
conjugate vaccine in children with and those without HIV infection. NEngl J Med
2003;349(14):[ADDRESS_847469] Dis 2010;201(1):32 -
41.
41Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13 -valent 
pneumococcal conjuga te vaccine received market authorization in Europe. Expert Rev 
Vaccines 2010;9(3):[ADDRESS_847470] pneumococcal pneumonia in adults. N Engl J Med 2015;372(12):1114 - 25.
43Centers for Disease Control and Prevention. Licensure of a 13 -valent pneumococcal 
conjugate vaccine (PCV13) and recommendations for use among children --Advisory  
Committee on I mmunization Practices (ACIP), 2010.  MMWR Morb Mortal Wkly  Rep
2010;59(9):258 -61.
44Centers for Disease Control and Prevention. Licensure of 13 -valent pneumococcal 
conjugate vaccine for adults aged 50 years and older .  MMWR Morb Mortal Wkly  Rep
2012;61(21):[ADDRESS_847471] characteristics. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/human/001104/WC500057247.pdf. Accessed: 12 Sep 2016.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 12046European Medicines Agency. Prevenar 13 assessment report. 22 Jan 2015.  Available 
from: http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Assessment_Report_ -_Variation/human/001104/WC500186805.pdf. Accessed: 12 Sep 
2016.
47World Health Organization. WHO prequalified vaccines. Pneumococcal (conjugate). 
Prevenar 13. Available from: 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=221. Effective: 
20 Aug 2010. Accessed: 12 Sep 2016.
48World Health Organization. WHO prequalified vaccines. Pneumococcal (conjugate). 
Prevenar 13 multidose vial. Available from: 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=317. Effective: 
14 Jul 2016. Accessed: [ADDRESS_847472] of 13 -valent pneumococcal 
conjugate vaccination in invasive pneumococcal disease incidence and mortality  
[erratum appears in Clin Infect Dis 2014;59(12):1812]. Clin I nfect Dis 2014;59(8):
1066-73. 
50Steens 
A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7- valent 
pneumococcal conjugate vaccine with the [ADDRESS_847473] . Vaccine 2013;31(52) :6232 - 8.
51Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serot ypes in the 
13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(49):[ADDRESS_847474] of pneumococcal conjugate 
vaccine implementation in children in [LOCATION_009] betw een 2001 to 2014. Hum Vaccines
Immunother 2016;12(2):[ADDRESS_847475] Dis J 2012;31(3) :297-301.
54Flasche S, Van Hoek AJ, Sheasby  E, et al. Effect of pneumococcal conjugate 
vaccination on seroty pe-specific carriage and invasive disease in England: a 
cross -sectional study . PLoS Med 2011;8(4):e1001017.
55Williams SR, Mernagh PJ, L ee MHT, et al. Changing epi[INVESTIGATOR_407381] a [ADDRESS_847476] 2011;194(3):116 -
20.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 12156Munoz -Almagro C, Ciruela P, Esteva C, et al. Seroty pes and clones causing in vasive 
pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J
Infect2011;63(2):151- 62.
57Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children 
provokes new patterns of seroty pes causing invasive pneumococcal disease in adults and 
children. Am J Med Sci 2013;345(2):[ADDRESS_847477] 2012;18(2):176 -82.
59Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serot ypes and mortality  
following invasive pneumococcal disease: a population- based cohort stud y. PLoS Med 
2009;6(5):e1000081.
60Wroe PC, L ee GM, Finkelstein JA, et al. Pn eumococcal carriage and antibiotic 
resistance in young children before [ADDRESS_847478] Dis J
2012;31(3):249 -54.
61Cohen R, Varon E, Doit C, et al. A 13- year survey of pneumococcal nasopharyngeal 
carriage in children with acute o titis media following PCV7 and PCV13 
implementation. Vaccine 2015;33(39):[ADDRESS_847479] Dis 2016;62(9):1119 -25.
63Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal seroty pes and 
antimicrobial resistance after introduction of the 13- valent conjugate vaccine in the 
[LOCATION_002]. Antimicrob Agents Chemother 2014;58(11):6484-9. 
64Demczuk WHB, Martin I, Griffith A, et al. Serot ype distribution of invasive 
Streptococcus pneumoniae in Canada after the introduction of the 13
-valent 
pneumococcal conjugate vaccine, 2010 –2012. Can J Microbiol 2013;59(12):[ADDRESS_847480] of pneumococcal conjugate vaccines 
for children in high -and non -high-income countries. Expert Rev Vaccines
2017;16(6):[ADDRESS_847481]- PCV era: a s ystematic review and 
meta -analysis. PloS One 2017;12(5):e0177113.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
Protocol B7471011
Final Protocol Amendment 2, 01 April 2022
PFIZER CONFIDENTIAL
Page 12267Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 
2011–2014: characterization of new candidate 15-valent pneumococcal conjugate 
vaccine serot ypes 22F and 33F. 
Vaccine 2016;34(23):2527-30.
68Metcalf BJ, Gertz RE Jr, Gladstone RA, et al. Strain features and distributions in 
pneumococci from children with invasive disease before and after [ADDRESS_847482] 2016;22(1):60.e9 -.e29.
69Waight PA, Andrews NJ, L adhani SN, et al. Effect of the 13 -valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in England and Wales 4 y ears after 
its in troduction: an observational cohort study. Lancet Infect Dis 2015;15(5):535-43.
70van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of infant pneumococcal 
conjugate vaccination on seroty pe distribution in invasive pneumococcal disease among 
children and adults in [LOCATION_013] . PLoS One 2015;10(7):e0131494.
71Beall B, Chochua S, Gertz RE Jr, et al. A population -based descriptive atlas of invasive 
pneumococcal strains recovered within the US during 2015- 2016 [online supplementary  
material]. Front Micro biol 2018;9:2670. Available from: 
https://www.frontiersin.org/articles/10.3389/fmicb.2018.[ZIP_CODE]/full#supplementary -
material . Accessed: [ADDRESS_847483] 2019.
72International Committee on Harmonisation. Statistical Principles for Clinical Trials. I CH 
Harmonised Tripartite Guideline E9, February  1998.
73US Food and Drug Administration. Guidance for industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluat ion and Research; September 2007.
74World Health Organization, Expert Committee on Biological Standardization. Geneva, 
19 to 23 October 2009. Recommendations to assure the quality , safet y and efficacy  of 
pneumococcal conjugate vaccines (replacement of TRS 927, Annex 2). Geneva, 
Switzerland: World Health Organization; [ADDRESS_847484]
Document Name:	


		
Document Title:
 !"#$%!!"&'('$ !)$')"*'&)
)+), !$##& "- $$),"+	(*' )
 &#"
"'" .&-)*$ $ '),$ + )
Signed By: [CONTACT_1782](GMT) Signing Capacity
	((	12321 +45
	((	9229 +45
[COMPANY_003]
[COMPANY_003]